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The globally circulating strains of HIV-1 can be broadly classified into four 
phylogenetic groups: M (the "major"), O (the "outlier"), N and P. The M subgroup 
contributes to more than 98% of the globally circulating strains, and it is further 
subdivided into A, B, C, D, F, G, H, J, K and circulating recombinant forms 
(CRFs). Because of the error prone nature of the virus genome, HIV-1 is 
continuously undergoing genetic changes and subsequent transmission. Hence, 
the clinical management and control of HIV-1 are still facing challenges despite 
huge efforts to develop vaccines and therapeutics. HIV-1 has three structural 
and six regulatory proteins. HIV-1 Tat (trans-acting activator of transcription), is a 
101-amino acid regulatory protein encoded by two exons (exon 1: 1 to 72 
residues, and exon 2: 73 to 101 residues). Tat protein has been divided into six 
different functional domains (5 domains in exon1 and 1 domain in exon 2). It 
plays essential roles in the replication through viral mRNA and genome 
transcription from the HIV-1 LTR promoter. Tat is therefore a promising target for 
developing vaccines and therapeutics while Tat undergoes continuous amino 
acid substitutions. As a consequence, the virus escapes from host immunity. My 
study is therefore aimed to investigate the molecular evolution of HIV-1 Tat in 
globally circulating HIV-1 stains. 
For my study, I curated the HIV-1 Tat sequences from the Los Alamos 
National Laboratory (LANL) HIV sequence database. My study data sets 
contains the amino acid sequences from a total 45 countries from six different 
continents; Africa (8 countries), North America (5 countries), South America 
(11countries), Asia (9 countries), Oceania (1 country), and Europe (11 countries). 
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I first prepared a dataset of a total 1179 sequences to investigate the 
intersubtype genetic variation of Tat exon-1 in all major subtypes of HIV-1: A, B, 
C, D, F, G, H, J, and K from the available globally circulating strains up to 2013. 
Then, I further investigated the genetic divergence in full-length Tat of HIV-1 
subtypes B and C. For that, I prepared a new data set containing full-length 
HIV-1 Tat sequences of subtypes B (n=493) and C (n=280) collected from 
globally circulating strains. I performed phylogenetic tree, mutation, and 
selection pressure analyses to understand the genetic variability and evolution of 
HIV-1 Tat. Bayesian graphical model analysis (BGM) was done to detect the 
co-evolving sites from multiple alignments of amino acid sequence data and to 
identify significant associations among sites. Moreover, I also analyzed the 
evolutionary dynamics of Tat in subtypes B and C in a subset of dataset by a 
Bayesian coalescent-based approach using the BEAST package.  
The mean nucleotide divergence (%) among the analyzed Tat exon 1 
sequences of HIV-1 subtypes A, B, C, D, F, G, H, J and K were 88, 89, 90, 88, 86, 
89, 88, 97, and 97%, respectively. The second and fifth domains were found 
comparatively more variable among all subtypes. Site-by-site analysis of positive 
selection revealed that several positions in all subtypes were under significant 
positive selection. Positively selected sites were found in the first domain at 
positions 3, 4, 19; in the second domain at positions 24, 29, 32, 36; in the third 
domain at position 40; and in the fifth domain for the rest of the positions for all 
subtypes. Positions 58 and 68 in the fifth domain were positively selected in 
subtypes A, B, C and B, C, F, respectively. I also observed high variability within 
positively selected sites in amino acid positions.  
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In full length Tat sequences (both exon 1 and 2), positively selected sites, 
such as positions 68 and 70 in both subtypes, were located in the 
Tat-transactivation responsive RNA (TAR) interaction site located at fifth domain. 
Positively selected sites were also found in the sixth domain of exon 2, such as 
positions 75, 77, 80, 81 and 87 for both subtypes. Mutations of the exon 2 were 
found particularly at intimately-networked coevolving sites with exon1 in the 
fourth, fifth, and sixth domains. The mean estimated nucleotide substitution rates 
for Tat in HIV-1 subtypes B and C were 1.53x10-3 (95% highest probability 
density- HPD Interval: 1.09 x10-3 to 2.08x10-3)  and 2.14x10-3 (95% HPD 
Interval: 1.35 x10-3 to 2.91x10-3) per site per year, respectively, which is relatively 
low compared to HIV-1 structural proteins. In molecular clock analysis, the 
median times of the most recent common ancestors (tMRCA) were estimated to 
be around 1933 (95% HPD, 1907–1952) and 1956 (95% HPD, 1934–1970) for 
subtypes B and C, respectively. 
My study provides comprehensive and updated information on the HIV-1 
Tat genetic evolution in recently circulating strains at global level. The study 
results would be an important foundation for developing effective vaccine and 
Tat-targeted therapeutics. The study findings also accomplish to a better 
understanding the evolutionary changes in regulatory protein like Tat in process 
of HIV-1 evolution. Taken together, my study results contribute to those 






The basic facts of HIV 
The human immunodeficiency virus (HIV) (genus: Lentivirus, 
family: Retroviridae) is a single-stranded, positive-sense, enveloped RNA 
virus[1,2,3 ]. The length of the viral genome is about 9.8 kb including two viral 
long-terminal repeats (LTRs) located at both ends when integrated into the host 
genome [3]. The virus has two phylogenetically distinct types: HIV-1 and HIV-2. 
HIV-1 spreads all over world [3], however, HIV-2 confined to only West Africa [4]. 
The HIV-1genome encodes for three genes: Gag, Pol, and Env for making the 
structural proteins for new virus particle. In addition, the virus also encodes six 
genes: Tat, Rev, Vpu, Vpr, Vif, and Nef [3]. The regulatory genes encode 
proteins for controlling the ability of HIV to infect the host cells, replicate for the 
production of new viral copies of virus [3].  
The consequence of HIV infection in human and epidemiology of 
HIV-1 infection  
HIV mainly infects the human immune system and weakens 
host-defense systems. As a consequence, the infected person becomes 
immunodeficient and at risk of getting a wide range of infections and some 
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types of cancer. Lastly, HIV infection causes Acquired Immunodeficiency 
Syndrome (AIDS), which is regarded as the advanced condition of HIV 
infection. Chronic or infection for a long duration with ultimate progression to 
AIDS is the hallmark of HIV infection. HIV/AIDS is still one of leading causes 
of death all over the world. More than 35 million people across the globe are 
now living with HIV/AIDS, and in 2013, it caused an estimated 1.5 million 
deaths globally [5]. The globally circulating strains of HIV-1 can be broadly 
classified into four phylogenetic groups: M (the "major"), O (the "outlier"), N 
and P [3]. The M subgroup contributes to more than 98% of the globally 
circulating strains, and it is further subdivided in to A, B, C, D, F, G, H, J, K 
and circulating recombinant forms (CRFs) [3]. The estimated global 
prevalence of subtype C accounted for nearly half (48%) of all global 
infections; subtypes A and B caused 12% and 11% of infections, respectively, 
followed by subtypes G (5%) and D (2%). Subtypes F, H, J and K together 
caused less than 1% of infections worldwide [6]. 
The evolution of HIV-1 
Because of the error prone nature of the virus genome, HIV-1 is 
continuously undergoing genetic changes and subsequent transmission. Hence, 
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the clinical management and spread of HIV-1 are still facing challenges despite 
huge efforts to develop vaccines and therapeutics. Since it was first reported in 
1981[7], the HIV-1 virus has shown high genetic variability, generating highly 
divergent strains. The transmission of those HIV-1 variants is a dynamic process 
because of continuous intermixing among different strains due to increasing 
human mobility across the globe. From the HIV-1 virus' perspective, diversity in 
the genome significantly impacts the functionality and immunogenicity of the 
virus itself, and this diversity is estimated to be about 1% per year [8,9]. The 
possible reasons for such divergence are high error rate during reverse 
transcription [10] and increased virus production [11] due to comparatively fast 
replication kinetics [12]. On the other hand, HIV-1 rapidly evolves during the 
course of infection in response to selective pressure induced by the host's 
immune response [13]. The evolutionary characteristics of HIV-1 have mostly 
studied focusing its structural genes, Gag, Pol and Env in subtypes B and C in 
different high-risk groups [14-19]. However, the evolutionary changes in the 
regulatory proteins in the process of HIV-1 evolution have not been studied well. 
HIV-1 Tat and its functions 
Tat (trans-acting activator of transcription) is one of HIV-1 regulatory 
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proteins having 101-amino acid encoded by two exons (exon 1: 1 to 72 residues, 
and the exon 2: 73 to 101 residues) in most of the clinical isolates [20]. However, 
only exon 1 can exert all transcriptional activating properties and replicate the 
new viruses [3]. Tat plays a pivotal role in viral transcription and replication. It 
directly enhances the HIV-1 replication through interaction with HIV-1 long 
terminal repeat (LTR) promoter [21]. Tat can induce the expression numerous of 
cellular genes; it also acts as a neurotoxic protein [22], leading to dementia in 
advanced HIV-1 infected cases, known as AIDS dementia complex. As shown in 
Figure 1, Tat has been categorized into six different functional domains [3, 20, 
23]. The first domain (residues 1 to 21) is the N-terminal acidic domain 
consisting of a Pro-rich tract and a conserved Trp residue at the position 20 
(Trp20) [3, 20]. The second domain (residues 22 to 37) contains a highly 
conserved seven Cys tract at positions 22, 25, 27, 30, 31, 34, and 37 [3, 23]. The 
third domain (residues 38 to 48) contains a hydrophobic core sequence: 
43LeuGlyIleSerTryGly48 [23]. The fourth domain (residues 49 to 57) is a 
positively charged region composed of a well-conserved arginine-rich motif, 
49-ArgLysLysArgArgGlnArgArgArg-57, and acts as a transactivation response 
element (TAR) binding domain [24]. This domain has an extraordinary property 
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for nuclear localization [25, 26] and protein transduction, thus it has also been 
used to deliver various molecules inside the cells in vitro [27-32]. The fifth 
domain (residues 58 to 72) is a Gln rich region [4, 8], and the fourth and fifth 
domains (residues 49 to 72) are known as basic domains for transactivation [3, 
23, 33]. The sixth domain (residues 73 to 101) encoded by the exon 2 is known 
as RDG domain; this domain contains the highly conserved 
GluSerLysLysLysValGlu motif, which is related to optimal HIV-1 replication in 
vivo [34], thereby, the region may contribute to viral infectivity and binding to 
cell-surface integrins [35, 36, 37]. Taken together, Tat plays crucial role in HIV-1 
transcription and replication as well as in cell surface binding [38].  
Tat-based vaccines and antivirals  
Developing vaccines by blocking virus replication and disease 
progression is one of strategies for anti-HIV vaccine development [39]. 
Regulatory proteins like HIV-1 Tat is one of the promising target in this 
perspective as Tat plays a versatile role in viral gene expression, transcription, 
replication and consequently in HIV-1 disease progression. Therefore, the 
possibilities of Tat targeted vaccines have been discussing since long time [40]. 
Several vaccines were also designed with an aim to inhibit circulating Tat protein, 
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thereby, halting the disease progression [41-44]. It has been recently observed 
that anti-Tat antibodies can exert protective role in the HIV-1 disease 
progression [45]. In clinical trials, HIV-1 Tat B cell epitope vaccine showed 
promising results in reducing HIV-1 viral loads. Notably, a higher frequency of 
anti-Tat antibodies has been detected in asymptomatic HIV-infected individuals 
compared to progressed patients [46]. However, those vaccines sometimes 
exert ambiguous results in different patient groups, and mutations in the 
antigenic sites have been suggested an important cause of vaccine 
ineffectiveness for those cases [47, 48]. Examining the genetic variation at 
amino acid level is therefore useful to define the epitope presentation on Major 
Histocompatibility Complex (MHC) class I antigen for afferent immune response 
[48, 49]. Investigating the genetic variation of Tat in globally circulating strains 
would be an important foundation for making a consensus sequence for effective 
vaccine development. 
On the hand, Tat binds to hairpin structure, transactivation-responsive 
(TAR) RNA for transactivation and recruits a pair of host proteins, cyclinT/ cdk9 
to the RNA [3]. Blocking that Tat-dependent HIV transcription is one the clever 
anti HIV-1 therapeutic strategy. Therefore, several antivirals have been designed 
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to inhibit that Tat-TAR RNA interaction [50, 51]. For example-peptide-based 
inhibitors such as peptoids [52], Tat-mimicking substances, cyclic b-hairpin 
peptide causing conformational change have been developed and tested for this 
purpose [51, 53-54].   
Genetic variation of HIV-1 Tat and its impact 
Like other HIV-1 protein, Tat also exerts subtype and region specific 
genetic divergence which has a huge impact on its functionality and 
pathogenesis of diseases progression. It has been previously reported that the 
genetic variations observed in Tat in major subtypes like B and C have impact on 
the functionality of protein and also its effect on the HIV-1 pathogenesis [55, 56]. 
It has been previously reported that Tat protein in subtype B in exhibits higher 
ability in viral replication and induction of TNF- α and and IL-6 expression 
compared to subtype C [57]. Furthermore, important structural and functional 
differences have also been reported in HIV-1 subtypes B and C. On the other 
hand, in virto experiments it has been found that HIV-1 Tat in subtype C showed 
greater transcriptional activity in the Jurkat CD4+ T cell line compared to 
subtypes B and E because of variations in the C-Tat sequence [58]. However, 
the genetic variation in other subtypes than B and C are not well-studied. The 
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genetic variation has been examined only in some regionally circulating strains. 
The Tat functional domain specific genetic variation has not been 
comprehensively studied yet. Vaccine effectiveness are greatly depends on 
designing the epitope in conserved sites based on the globally circulating strains. 
Therefore, any changes in antigenic sites greatly impair the efficacy of 
developed vaccines and anti-Tat antibodies [48, 59]. On the other hand, any 
mutations occurred in any TAT-TAR binding site dramatically reduce or impair 
the effectiveness of those therapeutics [3]. Thus, considering the importance of 
Tat in HIV pathogenesis and disease progression and its implication in 
developing vaccines, there should have a complete and compressive overview 
of its genetic variation at global level in recently circulating strains. It is therefore 
worthwhile to investigate the genetic variation of HIV-1 Tat for better 
understanding of its diversity in commonly circulating subtypes, which has an 
impact on clinical outcome of HIV disease as well as success of Tat-based 







1. To investigate the genetic variation of Tat exon 1 in all subtypes of HIV-1 M: A, 
B, C, D, F, G, H, J, and K. 
2. To examine the genetic variability of full-length Tat protein at the global level 
in major subtypes, B and C 
3. To investigate the evolutionary changes in HIV-1 regulatory protein, Tat in the 














Materials and Methods 
Sequence data 
For my study, the HIV-1 sequences were obtained from the Los Alamos National 
Laboratory (LANL) [60] and I prepared a total of three following datasets. 
Dataset 1 
        The HIV-1 Tat exon 1 amino acid sequences of were curated using the 
following options, “Alignment type: Web (all complete sequence), Year: up to 
2013, Organism: HIV-1, Region: TAT (exon 1), Subtype: All subtypes belonged 
to M (except A-K recombinant), DNA/Protein: DNA, Format: FASTA”. According 
to the LANL website, the curated alignments were published on the year after 
the sequences became available; therefore, the “up to 2013” alignment 
contains all sequences published before 2014. On July 3, 2014, 2156 
sequences were initially downloaded using ‘one sequence per patient’ option. 
The problematic sequences as defined by LANL’s pre-built search criteria, were 
excluded. Sequences likely to have been contaminated with laboratory strains 
were also excluded through this process. As recommended by LANL, I further 
checked to ensure that none of the sequences contained ambiguous 
nucleotides, hypermutation, minor insertions, minor deletions, premature 
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termination codons, or different sequences from the same strains (verified by 
the strain name). Through this sorting process, I made a study data set of a total 
of 1179 sequences for subtypes A to K, which contained 71 amino acids 
encoded by 213 nucleotides (nt) from the positions 5831 to 6045 nt in exon 1 of 
the HIV-1HXB2 genome (GenBank accession No. K03455). The sequences data 
was obtained together with the information about the host, subtype, isolation 
year, and isolated country. The details information of the sequences regarding 
the continent of origin and other aforementioned information with GenBank 
accession numbers were mentioned in Appendix Tables 1a and 1b. A 
multiple-sequence alignment program, ClustalW, was used to align the 
nucleotide sequences without any gap. Consensus sequences were generated 
by aligning circulating primary isolates and selecting the most common 
nucleotide at each position. In this study, the three most common subtypes 
were B, C, and A, were shown here as 50.7% (n=598), 28.5% (n=336), and 
10.9% (n=128) of the sequences obtained, respectively. The following amounts 
of the total number of sequences were for other subtypes: D (4.4%, n=52), G 
(2.5%, n=30), F (2.3%, n=27), H (0.3%, n=4), J (0.2%, n=2), and K (0.2%, n=2). 
It is worthwhile to mention that this distribution of HIV-1 subtypes to some extent 
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reflects the publicly available and published sequence data, not the global 
prevalence of subtypes that constitute the HIV pandemic. 
Dataset 2 
In order to investigate the genetic divergence of full-length Tat in HIV-1 in 
subtypes B and C, Tat sequences were obtained from the ‘Web alignment’ in the 
LANL. The sequences were downloaded on February 2, 2014. A total of 2156 
sequences were downloaded initially. Sequence data of the other subtypes than 
subtype B or C, and of circulating recombinant forms (CRFs) were then excluded. 
Consequently, totals of 713 and 353 sequences for subtype B and subtype C, 
respectively, were obtained. The sequence data for full-length coding regions of 
Tat were used after eliminating the problematic sequences. The reference 
strains for subtype B and C sequences were also obtained from the Los Alamos 
HIV-1 sequence data base. The reference sequences were also downloaded on 
February 2, 2014. As the reference sequences, accession numbers AY423387 
(Europe), AY173951 (Asia), and AY331295 (North America) for subtype B and 
AF067155 (India), U52953 (South America), and AY772699 (Africa) for subtype 
C were used for alignment. Finally, I prepared a data set of totals of 493 and 280 
sequences for subtype B and subtype C, respectively, which contained 100 
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amino acids encoded by 300 nucleotides (nt) from the positions 5831 to 6045 nt 
in exon 1 and  8379 to 8463 nt in exon 2, respectively of HXB2 genome 
(GenBank accession No. K03455). A multiple-sequence alignment of the 
nucleotide sequences (without any gap) was made using the ClustalW [61]. The 
divergence of sequences was schematically visualized using Weblogo [62]. The 
sequence data sets contained sequences from a total 45 countries from six 
different continents; Africa (8 countries), North America (5 countries), South 
America (11countries), Asia (9 countries), Oceania (1 country), and Europe (11 
countries). Like Dataset 1, the sequences data was obtained together with the 
information about the host, subtype, isolation year, and isolated country. The 
details information of the sequences regarding the continent of origin and other 
aforementioned information with GenBank accession numbers were mentioned 
in Appendix Tables 2a and 2b. 
 
Data set 3 
Next, another subset of data was made from the dataset 2 to investigate the 
evolutionary dynamics and molecular dating of Tat in HIV-1 subtypes B and C. In 
order to better determine the relationship between sequences from different 
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geographic areas, I attempted to include sequences from every country for both 
subtypes. Through this sorting process, I finally prepared a dataset of 135 and 
53 sequences for subtypes B and subtype C, respectively. Like dataset 1 and 2, 
the sequences data was obtained together with the information about the host, 
subtype, isolation year, and isolated country. The details information of the 
sequences regarding the continent of origin and other aforementioned 
information with GenBank accession numbers were mentioned in Appendix 
Tables 3a and 3b. 
Phylogenetic tree analysis 
In case of HIV-1 Tat exon 1 (data set 1), the phylogenetic tree was 
constructed using the Neighbor-Joining method. Evolutionary distances were 
computed following the Tamura-Nei [63] method and are in units representing 
the number of base substitutions per site. A discrete Gamma distribution was 
used to model evolutionary rate differences among sites (5 categories). The tree 
was drawn to scale, with branch lengths measured in the number of substitutions 
per site. Evolutionary analyses were conducted using Molecular Evolutionary 
Genetic Analysis (MEGA) version 6 [63]. The reliability was estimated from 
1,000 bootstrap replicates. Simian immunodeficiency virus (SIV) sequence, 
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CPZ.US.85.US_Marilyn.AF103 was used as the out-group to root the tree. 
FigTree v1.3.1 (available at: http://tree.bio.ed.ac.uk) was used for the 
visualization of the tree [65]. 
In case of full-length Tat (dataset 2), the phylogenetic tree was 
constructed by the Maximum Likelihood method based on the General Time 
Reversible model, which is the best model tested by model test in Molecular 
Evolutionary Genetic Analysis (MEGA) version 6 [63]. A discrete gamma 
distribution was used to measure the evolutionary rate differences among sites 
(5 categories) and the analyses were done using 1,000 bootstrap replicates. The 
tree was rooted by using following reference strain sequence: simian 
immunodeficiency virus (SIV), CPZ.US.85.US_Marilyn.AF103. 
Selection analysis 
 Global (ω) value of relative rates of non-synonymous (dN) and 
synonymous (dS) substitutions were calculated to measure the positive 
selection strength [66]. All analyses were carried out using the online 
Datamonkey facility [66-68] after identifying the best fit model from every 
possible time-reversible model. Positive selection pressure analysis was 
performed at whole gene and site-by-site codon level using three likelihood 
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methods: single-likelihood ancestor counting (SLAC), fixed effects likelihood 
(FEL), and interior branches Fixed Likelihood (iFEL). Briefly, in the SLAC method, 
the mean ratio of non-synonymous changes per non-synonymous site (dN) and 
the synonymous changes per synonymous site (dS) were measured using SLAC 
which considered inferred ancestral sequences for each internal node in a 
phylogeny using a codon model and then, calculated the synonymous and 
non-synonymous mutations by comparing each codon to its immediate ancestor. 
The FEL method is based on maximum-likelihood estimates. This method 
estimates the ratio of non-synonymous to synonymous substitutions on a 
site-by-site basis for the entire tree. iFEL is principally the same as FEL, except 
that selection is only tested along the internal branches of the phylogeny. To 
detect co-evolving sites from multiple alignments of amino acid sequence data 
and to identify significant associations among sites, Bayesian graphical models 
(BGM) method was used in Spidermonkey through the Datamonkey web-based 
interface [69]. 
Estimation of evolutionary rates and dates by molecular clock 
analysis 
For examining the evolutionary dynamics of HIV-1 full length Tat (data 
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set 3), a multiple-sequence alignment of the nucleotide sequences (without any 
gap) was constructed using ClustalW. I first tested sequences saturation 
(phylogenetic signal) which is useful for the phylogenetic analysis. Then, I 
performed Xia’s test implemented in DAMBE (available at: 
http://dambe.bio.uottawa.ca/dambe.asp). The substitution rate and timing of the 
most recent common ancestor (tMRCA) of subtypes C and B were estimated by 
BEAST v1.8.1 [71] using dataset 3.The GTR+Γ+I substitution model was used in 
all runs as it was selected by the program, JmodelTest 2.1.6 [70]. Following the 
procedure described in the previous study [15], BEAST analysis was done using 
normal distribution with a mean of 2.5x10-3 and standard deviation 5x10-4 prior 
using three different molecular clock models: strict relaxed, uncorrelated 
exponential, and relaxed uncorrelated lognormal [72,73]. The strict clock model 
was best for subtype C; the exponential relaxed clock model was best for 
subtype B, as revealed by a Bayes factor analysis performed in Tracer v.1.6. 
However, in the case of subtype B, this model showed extremely large 95% HPD 
intervals that caused convergence problems. I therefore considered strict clock, 
which was the second best model for subtype B (With sub-sampling performed 
every 2.56105 steps, MCMC simulations were run for 2.56108 chain steps and 
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analyzed by Tracer. For each tested prior, I considered a value above 250 to be 
an effective sample size (ESS). The Maximum Clade Credibility (MCC) tree ,with 
time scale,  was created  using Tree Annotator v1.8.1 with a burn-in of the first 
hundred trees and illustrated using Fig tree version 1.4.2 [74]. 
Demographic dynamics 
Phylodynamic analysis of the HIV-1 virus was performed using the 
Full-length Tat (data set 3) to determine epidemiological and phylogenetic 
patterns of global diversity. The phylodynamic histories of HIV-1 subtypes B and 
C were estimated from the Tat gene sequences using Bayesian skyride, which is 
an extension of the Bayesian Skyline Plot (BSP) implemented in BEAST. In 
Bayesian skyride analysis, changes in population size between the intervals are 
smoothed, and thus, I could assume gradual changes in population size using 
the time-ware prior [73]. Notably, Gaussian Markov random field (GMRF) 
smoothing prior is used in Bayesian skyride analysis tool. A marginal posterior 
distribution of the demographic inference was estimated using the Bayesian 
MCMC method and the effective population size at the most recent time of 





Phylogenetic tree analysis  
To reveal the intersubtype sequence identity of HIV-1 Tat exon1, distant 
analysis was performed using the Maximum Composite Likelihood method.  
Sequence identities and mean nucleotide divergence for all subtypes of HIV-1 
Tat are summarized in Table 1. In phylogenetic tree analyses (Figure 2), the 
evolutionary distances of different subtypes of Tat exon 1, estimated by the 
Neighbor Joining (NJ) method, showed that subtype C was more closely related 
with CPZ.US.85.US_Marilyn.AF103 strain than other subtypes. From that 
analysis, it was also revealed that subtypes B and D were more closely related 
to each other than to other subtypes; notably, subtype D is considered an early 
clade of subtype B African variant. The genetic distance between the rest of the 
subtypes and the subtype C was small, especially between subtype A and 
subtype C. There was no evident monophyletic distribution by year of isolation or 
by country in any subtype which may indicate that the infections from subtypes 
were transmitted in a diverse and heterogeneous manner. 
In case of full-length Tat (dataset 2), analysis of the phylogenetic relationship 
was performed using the maximum likelihood (ML) tree based on the nucleotide 
25 
 
sequences of subtypes B and C (Fig 3a and b). The phylogeny of Tat in subtype 
B featured with well intermixing of sequences among the different continents. 
The wide genetic diversity and several poorly defined clusters were observed in 
the sequences particularly in the strains from USA, South America and Europe. 
However, Asian strains, especially Thai and Korean strains clustered together 
distinctly, may result from different single introduction. In subtype C, it was hard 
to define clear clustering (Figure 3b). In the tree, the majority of subtype C 
strains were found in Africa, and those African stains did not show any 
monophyletic distribution, and there was a interspersing of Asian, South 
American and European strains with African stains. Overall, I observed a slow 
and continuous introduction of new HIV-1 strains in different parts of the world 
with repeated cross-border transmission as reflected by diffuse distributions and 
intermixing of the different HIV-1 variants in both subtypes B and C.  
Mutation analysis  
The following percentages of conserved positions in different subtypes 
were found: subtype A, 42%; subtype B, 27%; subtype C, 23%; subtype D, 42%; 
subtype F, 55%; subtype G, 59%; subtype H, 69%; subtype J, 87%; and subtype 
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K, 89% (Figure 4 and Table 2). Overall, subtypes B and C exhibited more 
genetic variation compared to other subtypes.   
In the first domain (residues 1-21), most of the positions were found 
conserved in all subtypes. Subtypes B, C, A and F contained more substituted 
amino acids, especially at positions 7, 12, 19, and 21. At positions 7 and 12, the 
predominant amino acid was asparagine in all subtypes except subtype B where 
arginine and lysine were predominant, respectively. Notably, positions 7 and 12 
are well-recognized antigen binding sites [48]. At position 19, all subtypes except 
B and C mostly contained lysine, whereas there are 13 and 10 different types of 
amino acid substitutions present in subtypes B and C, respectively. Moreover, at 
position 21, the predominant amino acids were alanine and proline in all 
subtypes except subtype F, which contained proline, and subtypes J and K 
contained alanine only.   
The second domain (residues 22–37) was the most variable region for all 
subtypes. At position 24, commonly found amino acids were lysine and 
asparagine in subtypes A, B, C, D, F, and G, asparagine in subtype H, and 
interestingly, glutamine in subtypes J and K. However, more variations were 
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observed in that position in subtypes A, B, and C. At position 29, amino acid 
changes were commonly observed, and most of the subtypes contained mainly 
lysine except subtype C, which contained histidine, and in subtype J and K, it 
was arginine. At position 32, phenylalanine was present in all subtypes except H, 
J and K, where it was tyrosine. At position 36, a large number of variations were 
observed, particularly in subtypes B, C and A, in which valine was commonly 
found; in other subtypes, it was leucine.  
In the third domain (residues 38 to 48) and the fourth domain (residues 49 
to 57), most of the positions were relatively conserved except 39 and 40. Among 
the studied subtypes, variation of amino acids was mostly observed in subtype 
B. 
The fifth domain (residues 58 to 72) was found comparatively more 
variable in all subtypes. All positions except position 65 (mainly in subtypes B, C, 
D and H) and 66 (in all subtypes) were relatively conserved. Positions 58 to 60, 
62 to 64, 67, and 68 were found to be the most variable in subtype B. 
In mutational analysis of full-length Tat of HIV-1 (dataset 2), the amino 
acid sequences divergence in both subtypes B and C were illustrated by 
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sequence logo (Figure 5a and b). The detailed substitution positions in each 
domain were described below following HXB2 numbering in both subtypes (the 
position of amino acid, aa, which had major changes). 
 In the first domain (residues 1 to 21), positions 1, 11, 14, 15, and 16 were 
found completely conserved in both subtypes; in addition, Asp5 in subtype C 
was also completely conserved. Notably, Lys12Asn (90%) and Ala21Pro (53%) 
were frequently observed only in subtype C.   
 In the second domain (residues 22 to 37), among the conserved Cys 
positions, Cys27 in subtype B and Cys22 and Cys34 in subtype C were 
completely conserved. Lys28 in subtype B and His33 in subtype C were also 
found as completely conserved in my analysis. Cys31Ser was observed in 
subtype C (83%), and all sequences of subtype C in my data sets were 
substituted as Phe32Tyr.  
In the third domain (residues 38 to 48), mutations in all positions were 
found in this domain except Lys41 in subtype C and Gly48 in subtype B. In 
subtype C, 80% sequences were substituted as Ile39Gln. In both subtypes, most 
of the sequences contained Ala42Gly (99%). 
 In the fourth domain (residues 49 to 57), the consensus Arg-rich motif 
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provided two of the key functions of Tat, nuclear localization and membrane 
transduction [25-32], a total of 6 Arg at the positions 49, 52, 53, 55, 56, and 
57. There was no conserved Arg position found in subtype B. Only positions 49 
and 55 were found conserved in subtype C accompanied with Arg57Ser 
substitution predominantly (88%).   
In the fifth domain (residues 58 to 72), only Gln66 was conserved in both 
subtypes; besides, Gln72 was almost completely conserved in subtype B and 
subtype C. For other sites, His59Pro substitution was apparent in both subtypes 
(81% and 95% in subtype B and C, respectively). In addition, Asn61Asp (64%) 
and Asn67Val (44%) in subtype B, and also Gln60Pro (89%), Asn61Ser (92%), 
Gln63Glu (75%), Thr64Asp (87%), Ala67Asn (73%), and Lys69Ile (61%) 
substitutions were frequently found in subtype C.   
The sixth domain is (residues 73 to 101) also known as the RGD 
(Arg-Gly-Asp) domain, and RGD is a ligand for several integrins, which play 
important roles in HIV replication and cell surface binding [35, 75, 76]. Even 
though representative conserved domain in Tat was well maintained in both 
subtypes, genetic variation in the sixth domain was observed of our data set.  In 
subtype B, 87Ser (77%) was most frequently found with many different 
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substitutions in small percentages at other positions of exon 2. In subtype C, 
high frequencies of substitutions were observed, including Thr74Leu (92%), 
Pro77Thr (79%), Pro84Ser (80%), Lys85Glu (89%) and 87Ser (95%) indicating 
that this domain is also variable. In Tat exon 2 of subtype C, the frequently 
observed substitutions were 93Ser (98%) and 94Lys (97%). Overall, genetic 
variation was found in the fourth, fifth, and sixth domains, which may have an 
impact on the functional properties of Tat, such as Tat-TAR interactions, protein 
transductions as well as cell surface binding and replication.   
Selection analysis 
The relative ratios (ω) of non-synonymous (dN) to synonymous (dS) 
substitutions for the nucleotide sequence of Tat exon 1 of all subtypes except 
subtypes H, J and K are shown in Figure 6. For subtypes H, J and K, selection 
pressure analysis could not be performed because of an insufficient number of 
eligible sequences. Interestingly, subtype F had the highest ratio value, followed 
by subtype B, then subtype G. In contrast, site-by-site tests of positive selection 
revealed that several positions in all subtypes were under significant positive 
selection by all three methods, the FEL, iFEL, and SLAC methods (Table 3). All 
positively selected codons selected by either one or two or three aforementioned 
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methods with statistical significance calculated are shown in Table 4. Positively 
selected sites were found in the acidic region at positions 3, 4, 19; in the 
cysteine-rich region at positions 24, 29, 32, 36; in the core domain at position 40; 
and in basic domain for the rest of the positions for all subtypes. Positions 58 
and 68 in the basic domain were selected in subtypes A, B, C and B, C, F by all 
three methods, respectively. Position 70 was also commonly selected only in 
subtypes B and C. In subtype D, positions 19 and 62 were positively selected; 
these two positions were also selected in subtype A. There was no positively 
selected position found with the SLAC method in subtype F. However, positions 
3 and 68 were selected using the FEL and iFEL methods. For subtype G, 
position 29 was positively selected by all three methods. Relative amino acid 
frequencies at positively selected codon position determined using the SLAC, 
FEL and iFEL methods in different subtypes are shown in Figure 7.  
Remarkably, in case of full-length Tat (dataset 2), a total of 23 and 18 amino acid 
positions in subtypes B and C, respectively, were found under significant 
positive selection based on the FEL, iFEL and SLAC methods. The detailed 
positively selected codons with statistical significance were calculated with 
SLAC, FEL, and iFEL methods as shown in Figure 8 and Table 5. Position Thr40 
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in the third domain was positively selected in both subtypes by all three methods. 
I found several positively selected sites in the basic region of Tat, such as Ser68 
and Ser70 in both subtypes; His59, Asn61, Ser62, and Thr64, His65 in subtype 
B; and Ala58, Ala67, and Leu69 in subtype C. In both subtypes of exon 2, Ser75, 
Pro77, Asp80, Pro81, and Ser87 were positively selected by all 3 methods. 
Bayesian graphical model (BGM) analysis 
 To identify coevolving sites among the substitutions, especially positive 
selection sites, BGM analysis was further performed. A total of 10 and 6 pairs of 
interacting sites were identified in Full-length Tat in subtypes B and C, 
respectively (Figure 9). In general, the coevolving sites appeared to be more 
intimately networked and primarily involved in exon 2 with different important 
domains of exon 1 particularly with basic domain as shown in Figure 9a and b; 
however, the posterior probabilities were not statistically significant.  
Substitution rate 
 The mean estimated substitution rates for subtypes B and C were 
1.53x10-3 (95% HPD Interval: 1.09 x10-3 to 2.08x10-3) and 2.14x10-3 (95% HPD 
Interval: 1.35 x10-3 to 2.91x10-3) per site per year, respectively (using date set 3). 
The mean substitution rate was lower in subtype B than subtype C according to 
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analyses using all three models (Figure 10). Notably, evolutionary potential of a 
population is expressed by evolutionary rate, which indicates the number of 
mutations that are fixed per unit of time in the virus population. Bayesian MCMC 
method was used to estimate rates of evolution; the details are shown in Table 6.  
Molecular dating analysis  
 Bayesian MCMC methodology was used to calculate the time of the 
most recent common ancestors (tMRCAs) of the sequences of subtypes B and 
C taken from the global sequences available in the Los Alamos database. The 
median dates of tMRCAs were estimated to be around 1933 (95% HPD, 1907 to 
1952) and 1956 (95% HPD, 1934 to1970) for subtypes B and C, respectively, 
with a Bayesian model. According to my analysis, subtype C appeared in the 
global population two decades after the introduction of subtype B. 
In case of subtype B, South American strains were introduced around 
the 1940s, whereas most of the North American strains appeared around the 
middle of 1950s. Asian strains evolved in the middle of the 1940s; strains 
originating from China, exhibited two peaks: one was from the middle of the 
1960s to the middle of the 1970s, and another was from the middle of the 1980s 
to the middle of the 1990s. African strains mainly evolved around the middle of 
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1970s. European strains were introduced at various times, ranging from the 
early 1950s to the early 1980s (Figure 11a). In case of subtype C, African strains 
were introduced in the middle of the 1960s; however, most of these strains 
emerged during the 1970s. Asian strains were first introduced in the early 1970s. 
European strains emerged earlier than Asian strains, and American strains 
emerged around the late 1970s (Figure 12a). 
Phylodynamic analysis 
Temporal changes in genetic diversity (population size) were observed 
using a GMRF skyride coalescent model. This analysis demonstrates that the 
early expansion of subtype B was quite rapid, but the duration was relatively 
short with a dispersion occurring during the late 1980s. There was an 
exponential escalation in the occurrence of infections from 1960–1970 to the 
early 1990s with an increasing trend up to the 2010s (Figure 11b). The 
demographic history of HIV-1 C exhibited a relatively slow occurrence rate until 
the late 1980s, and then, there was a sharp increase in occurrences up to the 
end of the 1990s. Thereafter, the rate of occurrence has gradually slowed 
(Figure 12b). This trend was similar for all three models in both subtypes with a 




In my study, the different subtype distributions of Tat exon 1 were broadly 
similar (phylogenetically) to estimated distributions of other genes like Gag, Pol, 
and Env; notably, those sequences were obtained using the Los Alamos 
sequence compendium published in 2012 [77]. I observed a 15 to 22% variation 
among the Tat sequences of nine HIV-1 subtypes. On the other hand, as 
reported previously, the genetic variation in Env amino acid sequences was 
about 25 to 35% among those nine subtypes [78], whereas in Gag and Pol , the 
genetic variation were approximately 14% [79] and 22 to 23% [80. 81], 
respectively.  
It is apparent in all trees that the branch lengths of the trees is not 
influenced by sequence length but rather by the density of nucleotide variation in 
each gene irrespective of phylogenetic method used. In other words, the faster a 
gene evolves, the longer the branch lengths will be versus more slowly evolving 
gene over the same time interval. The evolving pace of a gene is governed by 
several factors, most importantly by mutation rate and selection pressure. The 
variability in subtype distributions of HIV-1 Tat may increase over time as HIV-1 
transmission in different regions of the world continues because of diverse risk 
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behaviors and high mobility of the infected people [82]. Notably, subtype-specific 
differences in transmissibility and pathogenesis may not always lead to 
significant changes in subtype distribution in different populations; rather, those 
differences might be ecologic [83]. Therefore, the association between specific 
subtypes and a unique mode of transmission has yet to be established.  
The genetic complexity of the global HIV-1 epidemic is increasing due to 
the continuous molecular evolution of existing subtypes [84]. High variability 
within positively selected sites was observed possibly due to the fact that those 
sites are under diversifying selection. Notably, positive selection signifies genetic 
evolution and changes in antigenic sites for the binding of a virus to a host cell 
and also for exerting the host immune response against the infection [85]. In our 
analysis, the majority of selected amino acid residues were found in domains 2 
and 5 of HIV-1. Domain 2 is known as the highly conserved cysteine rich domain 
containing cysteine at seven positions. As revealed by previous studies, any 
amino acid change in this domain affects the phenotypic characteristics of Tat 
since this region is responsible for making disulfide bonds [86, 87] and regulating 
CCR5 expression in monocytes [88]. Domain 5 plays an important role in cell 
surface binding and internalization, and any changes in this domain also 
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influence the functionality of Tat [35, 36]. Relatively few positively selected 
variants were detected at the N terminus of Tat exon 1 between codons 1 to 21, 
and TAR binding site, a functionally important region. In addition to being 
conserved and negatively selected, those regions contain several experimentally 
defined cytotoxic T-lymphocyte (CTL) epitopes [48]. Taken together, the amino 
acid changes of those two domains may have functional consequences as 
shown in a previous study [89]. However, further in vitro experiments are needed 
to prove those hypotheses. 
I found that positions encoded in exon 2 such as Ser75, Pro77, Asp80, 
Pro81, and Ser87 were positively selected. As reported previously, exon 2 plays 
a role in the kappa-light-chain enhancer of activated B cell-(NF-κB) dependent 
control of HIV-1 transcription in T cells [23, 90]. It has been previously reported 
that unlike laboratory-passaged strains, such as HIV-1HXB2 with premature stop 
codon at position 87, majority of HIV-1 strains encode 101 amino acids without 
any truncation beyond the position 86 [20]. I found Ser87 in subtypes B and C 
which was positively selected. As previously noted, the existence of two exons is 
essential to maintain stability of Tat in vivo [91]; therefore, this position may be 
crucial to maintain the functional stability of Tat. Again, mutations of the exon 2 
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were found particularly at intimately networked coevolving sites with exon 1 in 
the fourth, fifth, and sixth domains. This may also have an impact on HIV mRNA 
transcription through Tat-TAR interaction and initiation of reverse transcription, 
which were previously reported as influenced by genetic variation of Tat [23, 91]. 
Here I also studied the evolutionary dynamics and molecular dating of 
HIV-1 from the perspective of one of its regulatory proteins, Tat. Previously, 
HIV-1 evolutionary analyses were mainly performed on the virus' structural 
proteins, Env, Gag and Pol; however, updated genetic information targeting Tat 
is limited. My study results estimated that nucleotide substitution rates for Tat in 
HIV-1 subtype B and C were relatively low. Previous studies have shown that the 
estimated HIV-1 evolutionary rate was 1 to 17 x10-3 substitutions per site per year 
[16, 92]. To the best of my knowledge, this is the first report demonstrating 
substitution rates for the Tat gene in major HIV-1 subtypes. As reported 
previously, nucleotide substitution rates for the HIV-1 surface glycoprotein, Env, 
were within the range of 7.3–8.7 x10-3substitutions per site per year [92,93]. 
Notably, HIV-1 subtype B strains from both North America and Europe exhibited 
similar estimated evolutionary rates. The estimated nucleotide substitution rates 
of Pol in HIV-1 subtypes B and C strains from Central America were 2.8–4.7 x10-3 
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and 1.5-2.3 x10-3substitutions per site per year, respectively. Taken together, I 
found that the Tat gene exhibited a lower substitution rate than structural genes 
like Env and Pol. However, the reason for this variation is yet to be revealed.  
The current study results of tMRCA for HIV-1 subtype B Tat in the United 
States was 1954– 1955 with a variable rate of evolution obtained using the 
Bayesian approach. However, the tRMCA was found around 1967 using the 
strict molecular clock model. For external genes like Env, the tMRCA for HIV-1 
subtype B in the United States and Western Europe was likely to be around the 
middle of the 1950s to the late 1960s [16,93,94]. According to the Pol 
gene-based analysis, the spread of subtype B in America occurred through a 
single introduction event in the Caribbean region around 1964 (1950–1967). It 
has also been speculated that subtype B-driven epidemics in those regions 
might have started during that time [17]. On the other hand, subtype C was 
introduced around the same time in Africa [18]. As shown by tMRCA, the HIV-1 
Env gene in the Thai-B strains was estimated to have emerged in the mid-1980s 
[95]. The tMRCA for the HIV-1 subtype C Pol gene was estimated to be in the 
early 1970s; notably, these strains were introduced into the general population in 
several instances through heterosexual or mother-to-child transmission [15]. 
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Overall, the tMRCAs of HIV-1 Tat in subtypes B and C found in my study are in 
line with other genes of HIV-1.   
In the current study, I observed that epidemiological trends proceeded 
relatively slowly. The time span of HIV-1 epidemic often encompasses months or 
even years owing to slow inter-host transmission kinetics. Moreover, the chronic 
nature of the disease leads to the persistence of epidemics through diffusing the 
infection among vulnerable groups[96]. As described previously, the extent of 
transmissibility is influenced by the time period of infection dynamics as well as 
by the changing vulnerability of hosts after epidemics [97]. Infection from 
multiple genotypes in an individual host provides a low level of cross-immunity 
[98], which may lead to slow evolutionary kinetics of HIV-1 proteins. It is 
noteworthy to mention that using the appropriate phylodynamic approach is 
imperative when correlating an epidemic event to its underlying genetic changes. 
In this regard, a coalescent tree analysis was performed to determine the 
nucleotide diversity for each time unit within a given phylodynamic framework. 
The viral dynamics was measured using GMRF skyride analysis, which enabled 
me to measure the evolutionary dynamics of HIV-1 based on Tat.  
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  It is noteworthy to mention that in my study the analyses and 
interpretation were based on the available sequences in the LANL database. In 
my dataset, the total number of Tat exon 1 sequences under each subtype 
varies, and the number of sequences for HIV-1 subtypes B and C was greater 
than for other subtypes. Particularly, there were fewer available sequences for 
subtypes H, J, and K than other subtypes. However, as I mentioned earlier, this 
variation derives from the global distribution of HIV-1 subtypes; as a result, it 
influences the available deposited sequences in LANL. For example, there are 
more deposited sequences for subtypes B and C than for other subtypes as they 
account for about 60% of the total number of HIV-1 infections worldwide. Since 
the LANL sequence database is a widely recognized data source for HIV 
evolutionary studies, my analyzed data sets are representative and adequate 
enough for investigating the intersubtype genetic variation of HIV-1 Tat. However, 
the genetic variability of Tat in some subtypes like H, J, and K needs to be further 
clarified in a larger sample size. In evolutionary analysis, the current study 
results might not be completely compared with other published [16,19,93-95] 
results on structural genes due to a lack of uniformity in the analyzed variables, 
including insufficient information about the substitution model and limited 
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information about the protocol used. It is worthwhile to mention that the 
estimated time of origin or evolutionary rate often varies among the genes within 
a single virus strain. Moreover, homogeneity of an analyzed sequence dataset, 
methods of multiple sequence alignment, and different substitution models often 
generate some variations. Despite those variations and shortcomings, to the 
best of my knowledge, my study, for the first time, reports the evolutionary 
dynamics of HIV-1 Tat. Future study can focus on aforementioned issues to get 
an overview of the evolutionary dynamics of HIV-1 regulatory proteins. 
Conclusion  
Updating the genetic variation of Tat would be an important foundation for 
developing effective vaccine and intracellular single chain anti Tat-antibodies. 
Similarly, for developing Tat-targeted therapeutics, monitoring the target region 
at the amino acid sequence level should be prioritized as any major or minor 
genetic changes on those targets may lead to therapeutic failure. Genetic 
monitoring of HIV-1 Tat needs to be continued to understand the adaptive 
evolution of the HIV-1. My study results therefore accomplish in those 
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Figure 1: Functional domains of Tat. Schematic presentation of the domains of Tat 
exon 1 and 2 were highlighted (panel A): domain I (residues 1 to 21), an acidic/Pro-rich 
region; domain II (residues 22 to 37), a Cys-rich/Zn2 Finger domain; domain III (residues 
38 to 48), containing conserved Phe (F);  domain IV (residues 49 to 57, the basic 
domain); domain V (residues 58 to 72, a Glu rich domain); and domain VI (residues 3 to 
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Figure 2: Phylogenetic tree for the HIV-1 Tat exon-1. Figure shows Neighbor-Joining 
phylogenetic tree of Tat exon 1 sequences in different subtypes of HIV-1. The 
evolutionary distances were computed using the Tamura-Nei method with GTR +Γ5 
nucleotide substitution model in the 1000 bootstrap replicates, using the MEGA 6; the 
tree was visualized by Fig Tree v1.4.0. Branch colors were added to indicate different 
subtypes. SIV sequence, CPZ.US.85.US_Marilyn.AF103 was used as the out-group to 
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Figure 3. Phylogenetic analyses of full-length Tat in HIV-1 subtypes B and C. 
Maximum likelihood (ML) phylogenetic tree of HIV-1 subtypes B (panel A) and C (panel 
B) sequences based on 300 nucleotide sites of Tat gene nucleotide sequence. 
GTR+I+Γ4 nucleotide substitution model was employed with 1000 bootstrapped data 
sets, using the Molecular Evolutionary Genetics Analysis software ver. 6 (MEGA 6). 
Reference Tat sequences were also included. SIV sequence 
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Figure 4.  Amino acid variation in the Tat exon 1 in different subtypes. In the figure, 
rows indicate amino acid position according to HIV-1 HXB2 numbering, and columns 
indicate different subtypes. The intensity of colors reflects the number of amino acid 



















































Figure 5. Amino acid variation in Full-length Tat. Sequence logo shows the Full-
length Tat amino acid variation observed at positions 1 to 100 in both subtype B (panel 
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Figure 6. Selection profiles of the Tat exon 1 gene in different subtypes. The 
dN/dS (ω) values were calculated using the SLAC method. The X-axis shows different 




Roy et al. AIDS Research and Human Retroviruses 2015; 31(6): 641-648 
75 
 
Figure 7. Amino acid variation in positively selected sites in different subtypes of 
HIV-1 Tat exon-1. Figure shows the frequency of amino acid variations in each 
positively selected codon positions determined by SLAC, FEL and iFEL in different 
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Figure 8. Selection profiles of Tat in subtypes B (panel a) and C (panel b). 
dN-dS values were estimated by SLAC and scaled by the total codon tree length. Sites 








Figure 9.Co-evolving sites identified by Bayesian Graphical Models. Amino acid 
sites of the Tat gene of subtypes B (panel a) and C (panel b) were depicted as groups 
showing different sites. Each connection is associated with posterior probabilities for 






Figure 10: Substitution rates of HIV-1 Tat. The substitution rate was estimated by 
three molecular based models in both subtypes B and C with normal distribution with a 
mean of 2.5x10-3 and standard deviation 5x10-4 prior. Small bars at the top of each 





Figure 11. Phylodynamic and Bayesian tree with timescale of HIV-1 subtype B Tat. 
A) Maximum clade credibility tree with time scale obtained from the strict molecular 
clock. Time to the MRCA was shown by vertical lines and indicated in years at the 
bottom of the figure. B) Gaussian Markov random field (GMRF) skyride plot considering 
three molecular clocks (strict, exponential relaxed and lognormal relaxed). The X-axis 
represents the time in year. The Y-axis represents the HIV-1 Tat effective number of 
infections (genetic diversity). The black line marks the median estimate for effective 
population size and the blue shading showed region displays the 95% highest posterior 








Figure 12. Phylodynamic and Bayesian tree with timescale of HIV-1subtype C Tat. 
a) Maximum clade credibility tree with time scale obtained from the strict molecular 
clock. Time to the MRCA was shown by vertical lines and indicated in years at the 
bottom of the figure. b) Gaussian Markov random field (GMRF) skyride plot considering 
three molecular clocks (strict, exponential relaxed and lognormal relaxed). The X-axis 
represents the time in year. The Y-axis represents the HIV-1 Tat effective number of 
infections (genetic diversity). The black line marks the median estimate for effective 
population size and the blue shading showed region displays the 95% highest posterior 












                             






a Sequence identity is calculated with corresponding consensus sequences for each subtype  
b Mean nucleotide divergence is calculated by the number of base substitutions per site from averaging over all sequence pairs for each subtypes 




  A B C D F G H J K 
Sequence identity 
a
 (%) 83 83 85 82 81 86 81 78 80 
Mean nucleotide divergence 
b
 (%) 88 89 90 88 86 89 88 97 97 




Table 2:  Detail information about the amino acid variation in different subtypes of HIV-1 Tat exon 1  
Domain aa position of 
HIV-1HXB2 
strain 
  Subtype A 
(N=128) 








Acidic domain 1 1 M M(128) M(598) M(336) M(52) M(27) M(30) M(4) M (2) M(2) 
  2 E D(109), E(19) D(78), E(520) D(33), E(303) D(30), E(22) D(1), E (26) D(29), E(1) D(4) D(1), E(1) E(2) 
  3 P L(2), P(126) P(598) L(12), P(320), Q(3), S(1)  L(3), P(49) I(8), L(6), 
M(2), P(7), 
V(4) 
P(30) P(4) P(2) P(2) 
  4 V I(1),V(127) A(1), I(14), V(583) A(1), I(79), V(256) I(2), V(50) I(1)V(26) V(30) V(4) V(2) V(2) 
  5 D D(128) D(598) D(336) D(52) D(27) D(29), E(1) D(4) D(2) D(2) 
  6 P P(128) H(5), P(591), S(1), Y(1) H(6), P(330) H(1), L(1), P(50) P(27) P(30) P(4) P(2) P(2) 
  7 R D(1), K(6), 
N(113), S(8) 
K(24), N(31), R(466), S(77)  D(2), H(1), K(55), 
N(249), R(4), S(25) 
K(4), N(48) N(17), S(2), 
K(5), R(2), 
D(1) 
K(7), N(23) N(2),K(2) N(2) N(2) 
  8 L L(128) L(598) I(5), L(331) I(4), L(48) I(2), L(25) L(30) Q(2),L(2) I(1),R(1) I(2) 
  9 E A(1), D(5), 
E(122) 
A(4), D(4), E(588), K(1), 
Q(1) 
 A(1), D(5), E(330) D(2), E(50) D(25), E(2) E(30) E(4) E(2) E(2) 
  10 P P(128) P(597), A(1) P(336) P(52) P(27) P(30) P(4) P(2) P(2) 
  11 W W(128) W(598) W(336) W(52) W(27) W(30) W(4) W(2) W(2) 
  12 K E(1), H(1), K(7), 
Q(3), 
S(1),N(115)  
E(12), K(525), N(25), Q(28), 
R(8) 
E(4), H(1), K(29), N(299), 
Q(1), R(1), S(1) 
K(5), N(47) K(2), 
Q(1),N(24)  
N(30) N(4) N(2) N(2) 
  13 H H(128) H(596), Q(2) H(333), Q(1), R(2) H(52) H(26), Q(1) H(30) H(4) Q(2) Q(2) 
  14 P P(128) P(598) P(336) P(52) P(27) P(30) P(4) P(2) P(2) 
  15 G G(128) G(598) G(336) G(52) G(27) G(30) G(4) G(2) G(2) 
  16 S S(128) S(598) S(336) C(2), (S50) S(27) S(30) S(1), N(3) S(2) S(2) 
  17 Q K(1), R(4), 
Q(123) 
K(7), Q(569), R(22) H(1), K(2), R(6), Q(327) Q(52) Q(27) K(2), Q(28) Q(4) Q(2) Q(2) 
  18 P P(128) P(598) H(1), P(335) P(52) P(27) P(30) P(4) P(2) P(2) 
  19 K A(20), I(4), 
K(32), R(2), 
S(1), T(69) 
E(6), G(1),K(400),L(2), N(1),  
Q(19), R(159), S(7), T(2), 
V(1)  
A(5), D(2), E(18), G(1), 
H(1), I(4), K(229), L(2), 
N(12), Q(16),R(19),  S(9), 
T(18) 
E(2), G(4),K(11), N(1), 







R(1),Q(1), K(2) K(2) K(2) 
  20 T T(128) T(598) A(2), I(1), T(333) S(1), T(51) N(1), T(26) T(30) T(4) T(2) T(2) 
  21 A A(75), E(1), 
P(52) 
A(455), D(8), E(2), N(1), 
P(126), R(1), S(4), T(1) 
A(142), E(1), P(189), S(2), 
T(1), V(1) 
A(11), P(41) P(27) P(8), A(22) A(1),P(3) A(2) A(2) 
Cysteine-rich 
domain (domain 2) 
22 C C(128) C(597), S(1) C(335), G(1) C(1), R(51) C(27) C(30) C(4) C(2) C(2) 
  23 T N(44), S(80), 
T(4) 
N(126), P(1), S(5), T(466) N(269), P(1),S(8), T(58)  N(45), S(5), T(3) N(11), T(16) N(23), T(7) N(4) N(1),T(1) N(2) 
  24 N A(1), K(81), 
N(33), P(3), 
R(4), S(2), T(4) 
A(15), D(1), G(4), K(105), 
N(262), P(81), Q(3), R(1),  
S(62), T(64) 
A(5), H(1), K(162), N(92), 
P(12), Q(13), R(4), S(19), 
T(28) 
K(30), N(9), P(2), R(1), 
S(9) 
K(16), N(5), 
R(3), S(1), T(2) 
N(7), K(23) N(3), G(1) Q(2) Q(2) 
  25 C C(1280 C597, R1 C(336) C(52) C(27) C(30) C(4) C(2) C(2) 
  26 Y F(6),Y(122) F(26), H(3), Y(569) C(1), F(43), H(1), M(1), 
W(1),Y(289)  
H(4), Y(48) F(2), Y(25) Y(29), F(1) Y(4) Y(2) Y(2) 
  27 C C(128) C(598) C(336) C(52) C(27) C(30) C(4) C(2) C(2) 
  28 K K(128) K(598) K(336) K(52) K(27) K(30) K(4) K(2) K(2) 





A(13), E(3), G(4), I(4), 
K(439), M(3), N(1), Q(41), 
R(75), S(7), V(7), Y(1) 
A(10), C(9), F(4), G(3), 
H(102), I(3), K(68), L(5), 
M(1), N(1), Q(6), R(64), 










K(1), Q(2), N(1) R(2) R(2) 
88 
 
  30 C C(128) C(596), G(1), R(1) C(332), R(3), Y(1) C(52) C(27) C(30) C(4) C(2) C(2) 
  31 C C(128) C(592), S(6) C(51), G(52), S(281), T(2) C(52) C(27) C(30) C(1), S(3) C(2) C(2) 
  32 F F(8), L(1), 
W(30), Y(89) 
F(390), L(102), M(8), W(13), 
Y(85) 
F(4), Y(332) F(1), L(1), W(2), Y(48) F(27) W(28), Y(2) Y(1),F(3) Y(2) Y(2) 
  33 H H(127), Y(1) H(597), P(1) H(336) H(52) H(27) H(30) H(4) H(2) H(2) 
  34 C C(128) C(596), G(1), Y(1) C(335), R(1) C(52) C(27) C(30) C(4) C(2) C(2) 
  35 Q Y(3), V(2), T(1), 
Q(76), P(31), 
L(10), I(5) 
A(1), I(4),M(1), P(12),  
Q(578), V(1), Y(1) 
A(1), F(1), I(6), L(267), 
P(22), Q(32), R(1), T(2), 
V(4) 
L(1), Y(3), Q(48) C(1), H(1), 
P(1), Q(8), 
Y(16) 
Q(30) Q(4) P(2) Q(2) 
  36 V A(15), D(2), 
H(1), I(9),K(2), 
L(10), 
M(4),R(1),  S(7), 
V(73), Y(4) 
A(23), F(2), H(2), I(2), K(8), 
L(12), M(1), N(1), R(2),S(2), 
T(2),V(539), W(1), Y(1) 
A(25), D(1), F(1), H(1), 
I(2),K(2), L(1), R(2),  
S(6), T(1), V(294) 
C(1), H(2), K(1), L(20), 








L(2), M(2) L(1),V(1) L(1)I(1) 
  37 C C(128) C(598) C(336) C(52) C(27) C(30) C(4) C(2) C(2) 
Core domain 
(domain 3) 
38 F L(1), V(1), 
F(126) 
F(596), L(1), S(1) F(332), L(3), S(1) F(52) F(26), L(1) F(30) F(4) F(2) F(2) 
  39 I H(2), I(2), 
L(111), Q(11), 
S(1), V(1) 
E(1), G(1), I(258), L(52), 
M(68), S(2), T(207), V(9) 
R(1), Y(1),H(3), L(60), 
Q(271) 




L(30) L(4) L(2) L(2) 
  40 T H(6), K(36), 
N(78), Q(1), 
R(1), S(1),T(5)  
A(1), D(1), E(1), H(1), 
K(204), N(7), Q(20), R(51), 
S(12), T(300) 
A(4), K(70), N(6), R(12), 
S(2), T(242) 





K(4) K(1), Q(1) Q(2) 
  41 K K(128) K(597), Q(1) K(335),T(1) K(52) K(27) K(30) K(4) K(2) K(2) 
  42 A G(128) A(110), G(487), T(1) D(1), G(335) G(52) G(27) G(30) G(4) G(2) G(2) 
  43 L L(128) L(598) L(335), S(1) F(1), L(51) L(27) L(30) L(4) L(2) L(2) 
  44 G G(128) G(596), S(2) A(1), C(1), G(333),S(1)  G(52) G(27) G(30) G(4) G(2) G(2) 
  45 I I(127), V(1) I(598) T(3), V(1), I(332) I(50), V(2) I(27) I(30) I(4) I(2) I(2) 
  46 S F(1), S(127) C(1), F(14), I(1), L(1), P(1), 
S(564), V(3), Y(13) 
C(1), F(1), H(1), P(1), 
S(312), Y(20) 
S(52) S(27) S(30) Y(1), S(3) S(2) C(1),S(1) 
  47 Y Y(128) F(1), H(13), N(6), Y(578) H(2), N(4), Y(330) Y(52) H(3), Y(24) Y(30) Y(4) H(2) Y(1), N(1) 
  48 G G(128) G(598) C(1), D(2), G(333) G(52) G(27) G(30) G(4) G(2) G(2) 
Basic domain or 
TAR binding 
domain (domain 4) 
49 R K(1), R(127) R(598) R(336) R(52) R(27) R(30) R(4) R(2) R(2) 
  50 K K(126), R(2) K(598) K(336) K(52) K(27) K(30) K(4) K(2) E(2) 
  51 K K(128) K(597), N(1) E(1), K(333), R(2) K(52) K(27) K(30) K(4) K(2) K(2) 
  52 R R(123), W(5) G(1), Q(2),R(584), W(11) R(327), W(9) R(52) R(27) R(30) R(4) R(2) R(2) 
  53 R K(34), R(91), 
S(2), T(1) 
G(9), K(9), N(1), R(571), 
S(8) 
G(7), K(4), R(317), S(8) G(9), K(1), R(40), S(2) R(27) K(21), N(1), 
R(5), S(3) 
R1, S3 R(2) R(2) 
  54 Q H(18), 
K(1),L(2), P(13),  
Q(86), R(8) 
H(1), K(4), P(12), Q(571), 
R(9), S(1) 
K(3),P(5), Q(332), R(6) K(1), L(1), P(1), R(1), 
Q(48) 
Q(27) P(2), Q(2), 
H(26) 
Q(1), R(3) Q(2) Q(1), P(1) 
  55 R R(128) G(1), H(1), M(1), Q(1), 
R(594) 
R(336) R(52) R(27) R(30) R(4) R(2) R(2) 
  56 R R(127), Q(1) H(1), P(1), Q(3), R(593) H(1), R(335) Q(1), R(51) R(27) R(30) R(2),H(2) R(2) T(2) 
  57 R D(1), G(95), 
K(1), R(31) 
A(2), G(18), K(4), R(566), 
S(3), T(5) 
T(1), G(1), H(1), N(12), 
Q(1), R(25), S(295) 
G(6), K(4), S(1), T(1), 
R(40) 
R(27) A(5), G(18), 
R(6), S(1) 
G(1),A(1),R(2) A(1),S(1) T(2) 
Domain 5 58 A A(13), P(17), 
S(5), T(93) 
A(313), D(2), H(1), L(1), 
N(1), P(121), S(54), T(105) 
A(202), G(1), P(1), S(2), 
T(130)  






T(4) A(2) T(2) 
  59 H D(1), H(3), L(1), 
P(112), S(11) 
A(4), D(7), H(60), 
N(3),P(486),S(32),T(5), Y(1), 
H(5), P(321), T(3), S(7),  A(1), H(2), P(43), S(6) P(24), S(3) H(4), P(25), 
S(1) 
P(4) P(2) P(2) 
  60 Q H(33), P(8), 
Q(81), R(3), 
Y(3) 
D(5), E(34), H(13), K(13), 
L(6), N(5), P(52), Q(458), 
R(8), S(2), T(1), Y(1) 
A(6), H(1), L(3), P(287), 
Q(12), R(4), S(22), T(1) 








K(1), A(3) S(1),P(1) Y(2) 
  61 N C(2), D(1), 
G(13),R(9),  
S(98) 
A(2), G(500), H(16), N(48), 
S(31), Y(1) 
D(2), G(10), N(9), R(9), 
S(305), T(1) 




S(3),G(1) G(2) A(1), N(1) 
  62 S C(1), D(2), 
N(39), R(1), 
C(17), D(5),G(22),H(10) , 
N(57), R(20),  S(465), T(1), 
C(1), G(9), N(17)0, R(1), 
S(308) 
D(16), G(23), N(9), S(3) G(1), N(3), 
S(22), T(1) 
N(6), S(24) L(1),V(3) S(2) S(2) 
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S(84), Y(1) Y(1) 
  63 Q E(7), G(1), 
K(115), Q(2), 
T(3) 
A(2), E(91), K(76), P(49), 
Q(370), S(9), W(1) 
A(5), E(260), G(1), K(68), 
T(2) 








Q(4) K(2) K(1), E(1) 
  64 T A(1), D(120), 
N(7) 
A(37), D(29),G(3), 
H(1),I(26), N(63), P(10), 
R(1), S(20), T(406), V(2) 
T(1), S(8), N(8), G(12), 
E(2), D(299), A(6) 







D(4) T(1),N(1) N(2) 
  65 H H(128) D(29), H(491), N(55), P(1), 
R(11), Y(11), 
H(327), N(4), R(3), Y(1), 
S(1) 
H(45), N(4), Y(3) H(27) H29, R1 H(3),N(1) H(2) H(2) 
  66 Q Q(128) Q(598) Q(336) Q(52) Q(27) K(1), Q(29) Q(4) Q(2) K(2) 
  67 A D(4), H(1), I(4), 
N(108), S(2), 
T(9) 
A(167), D(54), E(16), G(36), 
I(11), K(1), L(1), N(3), R(1), 
S(10), T(9), V(289) 
A(1), D(79), H(2), I(1), 
K(1), N(240), S(5), T(7) 
A(1), H(2), P(43), S(6), 





T(1),N(2),D(1) D(2) D(2) 
  68 S F(1), H(2), 
L(11), P(109), 
S(4), T(1) 
A(18), D(12), F(3), 
H1(1),L(1), N(5), 
P(125),S(407), Y(11), T(5) 
F(6), H(8), I(5), L(159), 
N(1), P(144), S(13) 




P(30) L(1),H(1),S(1),P(1) P(2) P(2) 
  69 L I(84), K(1), 
L(4), T(2), V(37) 
I(14), V(5), S(1), P(7), L(571) I(223), L(21), T(2), V(90) I(34), L(4), V(14) I(1), L(1), 
V(25) 
I(3), V(27) I(4) I(2) I(1),L(1) 
  70 S P(89), Q(9), 
R(4), S(26) 
P(174), Q(5), S(419) L(2), P(34), R(1), S(299) P(47), Q(1), S(4) P(20), R(1), 
S(6) 
P(28), R(2) P(2),S(2) P(2) P(1),R(1) 
  71 K E(5), K(119), 
Q(3), N(1) 
A(1), D(1), E(44), K(537), 
N(8), Q(2), R(2), T(3) 
E(15), K(318), N(3) D(1), E(9), K(42) E(7), K(20) E(5), K(24), 
Q(1) 
K(4) G(1),E(1) K(2) 
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Table 3: Positively selected sites selected by all three (SLAC, FEL, iFEL) methods 
in different subtypes of HIV-1 Tat exon 1 
 
Foot notes: *In subtypes H, J and K, selection pressure analysis could not be performed because of insufficient number  
                   of eligible sequences. 
   #SLAC method could not detect any positively selected position  
    a according to HIV-1HXB2 numbering 
    b single-likelihood ancestor counting (SLAC) method 
                   c fixed effects likelihood (FEL) method 
                   d interior  branches likelihood (iFEL) method 
Subtype*  Codon
 a
 Domain p-value 







A 19 Acidic <0.05 <0.001 <0.05 
  36 Cysteine-rich  <0.001 <0.001 <0.001 
  40 Core <0.05 <0.001 <0.001 
  58 Basic  <0.001 <0.001 <0.001 
  62 Basic  <0.001 <0.001 <0.001 
  69 Basic  <0.05 <0.001 <0.05 
B 24 Cysteine-rich  <0.001 <0.05 <0.001 
  32 Cysteine-rich  <0.001 <0.001 <0.001 
  58 Basic  <0.001 <0.001 <0.001 
  59 Basic <0.001 <0.001 <0.001 
  61 Basic  <0.05 <0.001 <0.001 
  63 Basic  <0.05 <0.05 <0.05 
  64 Basic  <0.001 <0.001 <0.001 
  65 Basic  <0.001 <0.001 <0.001 
  68 Basic  <0.001 <0.001 <0.001 
  70 Basic  <0.001 <0.001 <0.001 
C 4 Acidic  <0.001 <0.001 <0.001 
  21 Acidic  <0.05 <0.05 <0.05 
  36 Cysteine-rich  <0.05 <0.05 <0.05 
  40 Core  <0.001 <0.05 <0.05 
  58 Basic  <0.001 <0.001 <0.001 
  67 Basic  <0.001 <0.05 <0.001 
  68 Basic  <0.001 <0.001 <0.001 
  69 Basic  <0.001 <0.001 <0.001 
  70 Basic  <0.001 <0.001 <0.05 
D 19 Acidic  <0.05 <0.001 <0.001 
  62 Basic  <0.05 <0.05 <0.05 
F 3 Acidic  Not detected# <0.05 <0.05 
  68 Basic  Not detected# <0.05 <0.05 
G 29 Cysteine-rich  <0.05 <0.05 <0.05 
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Table 4: Detail information about the positively selected codons with statistical significance in 
different subtypes of HIV-1 Tat exon 1 calculated by SLAC, FEL, and iFEL methods 
Subtype SLACa   FELb    iFELc   
  Position* p-value Position* p-value Position* p-value 
Subtype A 19 0.0175253 19 0.00977211 19 0.0235536 
  36 0.00270279 36 0.00704499 35 0.0450479 
  40 0.024587 40 0.000358346 36 0.00145854 
  58 5.94E-05 58 2.76E-05 40 0.00690747 
  59 0.0196127 59 0.0321661 58 9.73E-06 
  62 0.000124971 62 3.46E-05 62 0.00071199 
  67 0.0297202 67 0.00753005 69 0.0135648 
  68 0.0010292 68 0.000704223     
  69 0.0212549 69 0.0021765     
  70 0.0203055 70 0.0113633     
      71 0.0423675     
Subtype B 24 0.000259111 7 0.00936966 7 0.00255847 
  32 1.06543E-05 24 0.012083148 24 0.009146051 
  40 0.00341684 32 0.000254588 32 0.001172438 
  58 2.38942E-17 40 0.00269402 58 7.34248E-13 
  59 4.9532E-07 42 0.0135939 59 0.00862037 
  61 0.0165545 58 9.65893E-15 61 0.001074532 
  62 0.0021589 59 5.42127E-06 63 0.0312014 
  63 0.01439107 61 0.000176651 64 7.99525E-05 
  64 3.17905E-07 62 0.0132088 65 0.00998377 
  65 1.28295E-05 63 0.00228988 68 2.28406E-09 
  68 1.65095E-13 64 2.41611E-05 70 3.45268E-06 
  70 7.81209E-08 65 6.4801E-05     
      68 1.91599E-11     
      70 1.53501E-07     
Subtype C  4 9.68E-07 4 3.93E-07 4 2.55E-05 
 19 0.0112024 19 0.045844 21 0.0268247 
  21 0.00559645 21 0.0470325 29 1.12E-07 
  36 0.0137592 29 1.22E-07 31 0.0346563 
  39 0.0173557 36 0.0309755 36 0.0313345 
  40 0.000498035 40 0.00108228 39 0.0108953 
  58 1.28E-08 58 7.91E-08 40 0.0101595 
  59 0.00344666 59 0.00344738 58 5.96E-07 
  67 0.000426635 67 0.00121861 67 0.00022994 
  68 1.51E-17 68 7.77E-16 68 6.55E-15 
  69 2.59E-06 69 1.38E-07 69 3.47E-07 
  70 1.00E-05 70 6.95E-06 70 0.0242114 
  71 0.021025 71 0.048103     
Subtype D 19 0.00174976 19 0.000281545 19 0.000636232 
  58 0.000451093 53 0.0266086 62 0.00962657 
  59 0.0267532 58 6.53E-05     
  62 0.0146033 59 0.00908178     
  68 0.026916 62 0.0185503     
      68 0.00887027     
      69 0.0273611     
      70 0.0427388     
Subtype F Not detected   3 0.0418129 3 0.00895379 
      39 0.0389108 58 0.0206786 
      68 0.0499068 68 0.0207294 
      70 0.0278739     
Subtype G 29 0.0359576 29 0.0358406 29 0.00445438 
  61 0.0448835 58 0.0396735   





Foot notes: selection pressure analysis in subtypes H, J, and K could not be performed because of an insufficient  
   number of eligible sequences 
             * according to HIV-1HXB2 numbering 
             a single-likelihood ancestor counting (SLAC) method 
         b fixed effects likelihood (FEL) method 
         c interior  branches likelihood (iFEL) method 
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7 First (Acidic) <0.05 <0.05 <0.05 
24 Second (Cysteine-rich) <0.001 <0.001 <0.001 
32 Second (Cysteine-rich) <0.001 <0.001 <0.001 
40 Third  <0.05 <0.001 <0.05 
59 Fifth (Basic)  <0.001 <0.001 <0.001 
61 Fifth (Basic) <0.05 <0.001 <0.001 
62 Fifth (Basic) <0.05 <0.05 <0.05 
63 Fifth (Basic) <0.001 <0.05 <0.05 
64 Fifth (Basic) <0.001 <0.001 <0.001 
65 Fifth (Basic) <0.001 <0.001 <0.001 
68 Fifth (Basic) <0.001 0 <0.001 
70 Fifth (Basic) <0.001 <0.001 <0.001 
75 Sixth (Exon 2) <0.001 <0.001 <0.001 
77 Sixth (Exon 2) <0.001 <0.001 <0.05 
80 Sixth (Exon 2) <0.05 <0.001 <0.05 
81 Sixth (Exon 2) <0.001 <0.001 <0.001 
84 Sixth (Exon 2) <0.001 <0.001 <0.05 
85 Sixth (Exon 2) <0.001 <0.001 <0.001 
87 Sixth (Exon 2) <0.001 0 <0.001 
88 Sixth (Exon 2) <0.001 <0.001 <0.05 
90 Sixth (Exon 2) <0.05 <0.05 <0.05 
93 Sixth (Exon 2) <0.001 <0.001 <0.001 
98 Sixth (Exon 2) <0.001 <0.001 <0.001 
C 
4 First (Acidic) <0.001 <0.001 <0.001 
21 First (Acidic)  <0.05 <0.05 <0.05 
29 Second (Cysteine-rich) <0.05 <0.001 <0.001 
39 Third <0.05 <0.05 <0.001 
40 Third <0.05 <0.001 <0.05 
58 Fifth (Basic) <0.001 <0.001 <0.001 
67 Fifth (Basic) <0.001 <0.001 <0.001 
68 Fifth (Basic) <0.001 <0.001 <0.001 
69 Fifth (Basic) <0.001 <0.001 <0.001 
70 Fifth (Basic) <0.001 <0.001 <0.05 
75 Second Exon  <0.001 <0.001 <0.001 
77 Second Exon <0.05 <0.001 <0.05 
80 Second Exon <0.001 <0.001 <0.001 
81 Second Exon <0.001 <0.001 <0.001 
87 Second Exon <0.05 <0.05 Not selected 
95 Second Exon <0.001 <0.001 <0.05 
97 Second Exon <0.001 <0.001 <0.05 
100 Second Exon <0.05 <0.001 <0.001 
Foot note:  a according to HIV-1HXB2 numbering 
 b single-likelihood ancestor counting (SLAC)  
                  cfixed effects likelihood (FEL), and  
                  d interior  branches likelihood (iFEL) approach  
Grey colored rows indicate commonly selected sites in both subtypes. p-values were shown as <0.05 and <0.001.  












Table 6: Substitution rates and time of the most recent common ancestors (tMRCAs) of subtypes B and C for all 

























Strict -8861.6551 63.282 1.53E-03 1.03E-03 2.08E-03 1933 1931 1907 1952 
Exponential -8910.0671 41.921 1.50E-03 6.57E-04 2.53E-03 1917 1907 1837 1958 




Strict -3641.8741 10.648 2.14E-03 1.35E-03 2.91E-03 1956 1954 1934 1970 
Exponential -3636.6521 -26.721 2.13E-03 1.25E-03 3.05E-03 1946 1942 1911 1967 
Lognormal -3638.9247  - 2.14E-03 1.39E-03 2.88E-03 1955 1954 1935 1971 







Appendix Table 1a: Distribution HIV-1 Tat sequences of different subtypes (N=1179) by continent of origin (Data set 1)  
 
 
Continent A B C D F G H J K Total 
Asia 1 48 18 3 - 2 - - - 72  
(6.1%) 
Africa 79 3 293 15 10 17 1 1 2 421  
(35.7) 








- 330 4 1 - - - - - 335 
(28.4%) 






















Appendix Table 1b: Accession numbers of the different subtypes of HIV-1 Tat Exon-1 used in this study obtained 
from the Los Alamos National Laboratory (LANL) HIV sequence database (Data set 1) 
Subtype A (n=128) 
                    A1.CD.02.02CD_KTB035.AM000055 A1.CD.97.97CD_KCC2.AM000053 A1.CD.97.97CD_KTB13.AM000054 A1.CH.03.HIV_CH_BID_V3538_2003.JQ403028
 A1.CY.05.CY021.FJ388892 A1.CY.05.CY022.FJ388893 A1.CY.05.CY051.FJ388903 A1.CY.05.CY057.FJ388906 A1.CY.05.CY064.FJ388909
 A1.CY.05.CY106.FJ388925 A1.CY.05.CY121.FJ388932 A1.CY.05.CY140.FJ388938 A1.CY.06.CY164.FJ388946 A1.CY.06.CY171.FJ388950
 A1.CY.06.CY173.FJ388951 A1.CY.07.CY182.JF683737 A1.CY.07.CY196.JF683748 A1.CY.07.CY207.JF683759 A1.CY.07.CY208.JF683760
 A1.CY.07.CY213.JF683763 A1.CY.08.CY218.JF683767 A1.CY.08.CY230.JF683779 A1.CY.08.CY235.JF683782 A1.CY.08.CY236.JF683783
 A1.CY.09.CY243.JF683789 A1.CY.09.CY255.JF683798 A1.ES.05.X1608_8.FJ670519 A1.ES.06.X2110.FJ670523 A1.IT.02.60000.EU861977
 A1.KE.00.KER2008.AF457052 A1.KE.00.KER2009.AF457053 A1.KE.00.KER2012.AF457055 A1.KE.00.KNH1144.AF457066 A1.KE.00.KNH1207.AF457068
 A1.KE.00.KNH1209.AF457069 A1.KE.00.KNH1211.AF457070 A1.KE.00.KSM4024.AF457077 A1.KE.00.KSM4030.AF457079 A1.KE.00.MSA4069.AF457080
 A1.KE.00.MSA4070.AF457081 A1.KE.00.MSA4072.AF457083 A1.KE.00.MSA4076.AF457084 A1.KE.00.MSA4079.AF457086 A1.KE.00.NKU3005.AF457089
 A1.KE.01.ML1901PCR2.EU110095  A1.KE.01.ML1945.EU110088 A1.KE.02.ML1990.EU110092 A1.KE.06.06KECst_001.FJ623487 A1.KE.06.06KECst_005.FJ623481            
A1.KE.06.06KECst_006.FJ623475  A1.KE.06.06KECst_007.FJ623476 A1.KE.06.06KECst_009.FJ623480  A1.KE.06.06KECst_013.FJ623485 A1.KE.06.06KECst_016.FJ623483 
 A1.KE.06.06KECst_017.FJ623488 A1.KE.06.06KECst_019.FJ623478 A1.KE.06.06KECst_020.FJ623482 A1.KE.06.06KECst_021.FJ623477 A1.KE.06.06KECst_025.FJ623486
 A1.KE.06.06KECst_028.FJ623479 A1.KE.11.DEMA111KE002.KF716474 A1.KE.11.DEMA11KE001.KF716475 A1.KE.86.ML013_10.AY322184
 A1.KE.86.ML170_1986.AF539405 A1.KE.94.Q23_17.AF004885 A1.KE.97.ML605_3.AY322190 A1.KE.97.ML752.AY322193
 A1.KE.99.KNH1088.AF457063 A1.KE.99.KNH1135.AF457065 A1.KE.99.KSM4021.AF457075 A1.RU.05.RU_560_1125_JA.JQ292895
 A1.RU.06.RU_915_1016.JQ292896 A1.RU.06.RU_915_1035.JQ292897 A1.RU.06.RU_915_1038.JQ292898 A1.RU.06.RU_SP_B_049.JQ292900
 A1.RU.07.Irkutsk_5.JQ292891 A1.RU.08.DEMA108RU003.KF716491 A1.RU.08.DEMA108RU004.KF716492 A1.RU.08.RUA001.JQ292893
 A1.RU.08.RUA007.JQ292894 A1.RU.10.10RU6617.JX500696 A1.RU.10.10RU6792.JX500695 A1.RU.11.11RU6950.JX500694 A1.RW.07.pR463F.JX236677
 A1.RW.07.pR880F.JX236678 A1.RW.11.DEMA111RW002.KF716472 A1.RW.92.92RW008.AB253421 A1.RW.92.92RW025A.AB287377
 A1.RW.93.93RW_024.AY713406 A1.RW.93.93RW037A.AB287379 A1.SE.94.SE7253.AF069670 A1.SE.94.SE7535.AF069671 A1.SE.95.SE8538.AF069669
 A1.SE.95.SE8891.AF069673 A1.SE.95.UGSE8131.AF107771 A1.SN.01.DDJ369.AY521631 A1.SN.96.DDJ360.AY521630 A1.TZ.01.A173.AY253305
 A1.TZ.01.A341.AY253314 A1.TZ.97.97TZ02.AF361872 A1.TZ.97.97TZ03.AF361873 A1.UA.00.98UA0116.AF413987 A1.UA.01.01UADN139.DQ823357
 A1.UA.01.01UAOD89.DQ823367 A1.UG.07.p191084.JX236669 A1.UG.07.p191845.JX236671 A1.UG.07.p9004SDM.JX236676 A1.UG.07.PP6_F3_A2.HM027823
 A1.UG.09.DEMA109UG001.KF716478 A1.UG.11.DEMA110UG001.KF859745 A1.UG.11.DEMA110UG009.KF716486 A1.UG.85.U455_U455A.M62320
 A1.UG.90.UG273A.L22957 A1.UG.90.UG275A.L22951 A1.UG.92.UG029.AB098332 A1.UG.98.98UG57134.AF484507 A1.UG.98.98UG57135.AF484508
 A1.UG.98.98UG57136.AF484509 A1.UG.98.98UG57142.AF484512 A1.UG.99.99UGG03379.AF484493 A1.UG.x.UG031.AB098330
 A1.UZ.02.02UZ0663.AY829210 A1.ZA.01.TV314.FJ647148 A1.ZA.04.04ZASK162B1.DQ396400 A2.CD.97.97CDKS10.AF286241
 A2.CD.97.97CDKTB48.AF286238 A2.CM.01.01CM_1445MV.GU201516 A2.CY.94.94CY017_41.AF286237 
Subtype B (n=598) 
                    B.AR.00.ARMS008.AY037269 B.AR.02.02AR114146.DQ383746 B.AR.03.03AR137681.DQ383748 B.AR.03.03AR138910.DQ383749 B.AR.04.04AR151263.DQ383751
 B.AR.04.04AR151516.DQ383752 B.AR.99.ARMA132.AY037282 B.AU.03.PS2008_Day182.DQ676875 B.AU.04.MS2004_37_016.EF178314
 B.AU.04.MS2004_37_122.EF178420 B.AU.04.MS2004_37_129.EF178427 B.AU.04.Phcsffull04.AY818644 B.AU.04.PS2016_Day380.DQ676879
 B.AU.93.MBC18_MBCC18.AF042102 B.AU.95.C24.AF538304 B.AU.95.C42.AF538305 B.AU.95.C76.AF538306 B.AU.95.C92.AF538307
 B.AU.95.MBCC54.AF042103 B.AU.96.MBCC98.AF042104 B.AU.96.MBCD36.AF042105 B.AU.99.1181.AF538302 B.AU.99.1182.AF538303
 B.AU.x.15888_30.AY624304 B.AU.x.8634991.AY857144 B.AU.x.VH_VHPCR.AF146728 B.BO.99.BOL0122.AY037270 B.BR.02.02BR002.DQ358805
 B.BR.02.02BR008.DQ358808 B.BR.02.02BR011.DQ358809 B.BR.02.02BR1013.JN692432 B.BR.02.02BR2025.JN692435 B.BR.02.02BR2032.JN692439
 B.BR.02.02BR2033.JN692440 B.BR.02.02BR2041.JN692443 B.BR.02.02BR2042.JN692444 B.BR.02.04BR1064.JN692433 B.BR.02.05BR1094.JN692470
 B.BR.03.03BR1020.JN692445 B.BR.03.03BR1046.JN692447 B.BR.03.BREPM1023.EF637057 B.BR.03.BREPM1024.EF637056 B.BR.03.BREPM1027.EF637054
 B.BR.03.BREPM1032.EF637051 B.BR.03.BREPM1033.EF637050 B.BR.03.BREPM1035.EF637049 B.BR.03.BREPM1038.EF637048 B.BR.03.BREPM1040.EF637047
 B.BR.03.BREPM2012.EF637046 B.BR.04.04BR1047.JN692450 B.BR.04.04BR1049.JN692451 B.BR.04.04BR1054.JN692453 B.BR.04.04BR1057.JN692455
 B.BR.04.04BR1068.JN692457 B.BR.04.BREPM1070.FJ195086 B.BR.05.05BR1074.JN692459 B.BR.05.05BR1077.JN692460 B.BR.05.05BR1078.JN692461
 B.BR.05.05BR1079.JN692462 B.BR.05.05BR1080.JN692463 B.BR.05.05BR1082.JN692465 B.BR.05.05BR1089.JN692467 B.BR.05.05BR1095.JN692471
 B.BR.05.05BR1101.JN692473 B.BR.05.05BR1104.JN692474 B.BR.05.05BR1107.JN692475 B.BR.05.BREPM1081.FJ195091 B.BR.05.BREPM1084.FJ195088
 B.BR.05.BREPM1093.FJ195089 B.BR.06.06BR1119.JN692480 B.BR.07.BP00047_RH01.JN687739 B.CA.06.502_1799_FL02.JF320427
 B.CA.96.WC10P_1.AY314044 B.CA.98.CANA3FULL.AY779550 B.CA.98.CANC10FULL.AY779557 B.CA.x.HND_DRPI039V01.DQ322225
 B.CH.00.CHLSM1SI0i0007251ppNFLG95.KC797171 B.CH.00.HIV_CH_BID_V3530_2000.JQ403023 B.CH.01.HIV_CH_BID_V3531_2001.JQ403024
 B.CH.01.HIV_CH_BID_V3534_2001.JQ403026 B.CH.02.HIV_CH_BID_V3527_2002.JQ403021 B.CH.02.HIV_CH_BID_V3539_2002.JQ403029
 B.CH.02.HIV_CH_BID_V4424_2002.JQ403044 B.CH.03.HIV_CH_BID_V4421_2003.JQ403043 B.CH.03.HIV_CH_BID_V4470_2003.JQ403045
 B.CH.03.HIV_CH_BID_V4474_2003.JQ403046 B.CH.04.HIV_CH_BID_V4408_2004.JQ403042 B.CH.08.CHLSM2SI5082i0803101ppNFLG8.KC797225
 B.CO.01.PCM034.AY561238 B.CU.99.Cu19.AY586542 B.CU.99.Cu43.AY586543 B.CY.05.CY018.FJ388890 B.CY.05.CY020.FJ388891
 B.CY.05.CY030.FJ388956 B.CY.05.CY032.FJ388898 B.CY.05.CY033.FJ388957 B.CY.05.CY035.FJ388958 B.CY.05.CY036.FJ388959
 B.CY.05.CY037.FJ388899 B.CY.05.CY055.FJ388904 B.CY.05.CY056.FJ388905 B.CY.05.CY065.FJ388910 B.CY.05.CY067.FJ388911
 B.CY.05.CY068.FJ388912 B.CY.05.CY070.FJ388960 B.CY.05.CY072.FJ388914 B.CY.05.CY074.FJ388915 B.CY.05.CY082.FJ388962
 B.CY.05.CY088.FJ388919 B.CY.05.CY093.FJ388923 B.CY.05.CY096.FJ388963 B.CY.05.CY110.FJ388927 B.CY.05.CY122.FJ403482
 B.CY.05.CY124.FJ388933 B.CY.05.CY130.FJ388934 B.CY.05.CY131.FJ388935 B.CY.05.CY142.FJ388965 B.CY.05.CY149.FJ388940
 B.CY.06.CY168.FJ388949 B.CY.07.CY181.JF683736 B.CY.07.CY184.JF683738 B.CY.07.CY188.JF683741 B.CY.07.CY189.JF683742
 B.CY.07.CY190.JF683743 B.CY.07.CY195.JF683747 B.CY.07.CY197.JF683749 B.CY.07.CY198.JF683750 B.CY.07.CY199.JF683751
 B.CY.07.CY201.JF683753 B.CY.07.CY202.JF683754 B.CY.07.CY204.JF683756 B.CY.07.CY214.JF683764 B.CY.07.CY216.JF683765
 B.CY.08.CY220.JF683769 B.CY.08.CY224.JF683773 B.CY.08.CY226.JF683775 B.CY.08.CY229.JF683778 B.CY.08.CY232.JF683781
 B.CY.08.CY237.JF683784 B.CY.08.CY238.JF683785 B.CY.09.CY241.JF683787 B.CY.09.CY244.JF683790 B.CY.09.CY250.JF683793
 B.CY.09.CY251.JF683794 B.CY.09.CY253.JF683796 B.CY.09.CY258.JF683801 B.CY.09.CY263.JF683805 B.CY.09.CY266.JF683807
 B.DE.03.HIV_DE_BID_V3307_2003.JQ403048 B.DE.86.HAN.U43141 B.DE.x.DEMBXXDE001.KC596067 B.DK.01.CTL_017.EF514705 B.DK.01.CTL_018.EF514706
 B.DK.01.CTL_030.EF514708 B.DK.01.CTL_035.EF514710 B.DK.01.CTL_041.EF514711 B.DK.04.PMVL_012.EF514699 B.DK.04.PMVL_013.EF514700
 B.DK.04.PMVL_018.EF514697 B.DK.04.PMVL_039.EF514703 B.DK.04.PMVL_049.EF514701 B.DK.07.PMVL_011.FJ694790 B.EC.89.EC003.AY173959
 B.EC.89.EC102.AY173960 B.ES.05.X1890.EU786672 B.ES.06.X1998.EU786676 B.ES.06.X2102.EU786677 B.ES.07.X2210_3.EU786679
 B.ES.07.X2231.EU786680 B.ES.08.ES_X2515_3.GQ372988 B.ES.08.P2008.FJ670531 B.ES.08.P2021_3.FJ853620 B.ES.08.X2425_2.FJ670525
 B.ES.08.X2510_2.FJ853622 B.ES.08.X2555_2.GU362883 B.ES.08.X2574_2.GU362886 B.ES.09.P2149_3.GU362881 B.ES.09.X2689_2.GU362885
 B.ES.10.DEMB10ES002.KC473842 B.ES.10.DEMB10VE001.JX140659 B.FR.08.DEMB08FR002.JX140654 B.FR.09.DEMB09FR001.KF716494
 B.FR.09.DEMB09FR002.KF716495 B.FR.11.DEMB11FR001.KF716496 B.FR.83.HXB2_LAI_IIIB_BRU.K03455 B.GA.88.OYI_397.M26727
 B.GB.03.MM33d12p.HM586187 B.GB.04.MM39d11p.HM586193 B.GB.05.MM43d368_GN1.HM586209 B.GB.05.MM45d22_GN1.HM586210 B.GB.83.CAM1.D10112
 B.GB.86.GB8_46R.AJ271445 B.GB.x.MANC.U23487 B.GE.03.03GEMZ004.DQ207940 B.GE.03.03GEMZ010.DQ207942 B.HK.06.HK002.FJ460499
 B.HT.05.05HT_129473.EU839603 B.HT.05.05HT_129696.EU839601 B.IN.x.11807.EF694037 B.JM.05.05JM_KJ108.EU839605
 B.JM.09.09JM_PF09XN.HM030559 B.JM.09.09JM_PF09YT.HM030560 B.JM.09.09JM_PF0B8J.HM030561 B.JM.09.09JM_PF0B97.HM030562
 B.JM.09.09JM_PF0B9L.HM030565 B.JP.00.DR2508.AB289588 B.JP.00.DR2510.AB287372 B.JP.01.DR388.AB289590 B.JP.03.285.AB428558
 B.JP.04.04JPDR6075B.AB221126 B.JP.04.DR5913.AB480696 B.JP.04.DR6174.AB480692 B.JP.04.DR6175.AB480694 B.JP.05.DR6538.AB287363
 B.JP.05.DR6737.AB287364 B.JP.08.08JP_NMC104_clone_01.AB731663 B.JP.09.09JP_NMC127_clone_07.AB731667 B.JP.11.DEMB11JP002.KF716497
 B.JP.12.DEMB12JP001.KF716498 B.JP.x.DR1673.AB564745 B.JP.x.DR1712.AB604946 B.JP.x.JRC03B.AB565496 B.JP.x.pJPDR0796B02.AB565478
 B.JP.x.pJRC57B09.AB641836 B.KR.03.03HJY8.JQ316131 B.KR.03.03KDE11.JQ316128 B.KR.03.03KGS5.JQ316132 B.KR.03.03YGS3.JQ316135
 B.KR.04.04CWS5.JQ316133 B.KR.04.04KJin8_1955.DQ295195 B.KR.04.04KJS8.JQ316130 B.KR.04.04KMK5.JQ316126 B.KR.04.04KYR8.DQ295196
 B.KR.05.05CSR3.DQ837381 B.KR.05.05YJN2.JQ316134 B.KR.12.12KYY10_10742.KF561441 B.KR.91.91OSG10.KF561442 B.KR.97.WK.AF224507
 B.NL.99.671_99T12.AY423381 B.PE.06.502_0491_wg5.JF320183 B.PE.06.502_0524_FL04.JF320008 B.PE.06.502_0648_FL02.JF320215
 B.PE.06.502_0841_FL04.JF320208 B.PE.06.502_2717_RH03.JF320230 B.PE.06.502_2794_FL05.JF320244 B.PE.07.502_0525_wg5.JF320191
 B.PE.07.502_1047_wg5.JF320226 B.PE.07.502_2254_FL6.JF320018 B.PE.07.502_2622_wg1.JF320189 B.PL.08.BP00074_RH02.JN687774
 B.PL.x.DEMBXXPL001.KC596069 B.PY.02.02PY_PSP0019.JN251896 B.PY.02.02PY_PSP0090.JN251901 B.PY.03.03PY_PSP0115.JN251906
 B.RU.04.04RU128005.AY682547 B.RU.04.04RU129005.AY751406 B.RU.04.04RU139089.AY751407 B.RU.09.09RU4457.JX500709 B.RU.10.10RU6629.JX500707
 B.RU.11.11RU21n.JX500708 B.TH.04.04TH317223.JN248321 B.TH.04.04TH803686.JN248333 B.TH.05.05TH356764.JN248344 B.TH.05.05TH357801.JN248346
 B.TH.05.05TH645189.JN248353 B.TH.05.05TH736580.JN248354 B.TH.06.AA010a_WG3.JX446800 B.TH.08.AA115c03R.JX448103 B.TH.90.BK132.AY173951
 B.TH.96.M149.DQ354119 B.TT.00.00TT_CRC50018.EU839607 B.TW.94.TWCYS_LM49.AF086817 B.UA.01.01UAKV167.DQ823362
 B.UA.01.01UAKV252.DQ823363 B.UA.01.01UAKV259.DQ823364 B.US.00.ES1_20.EF363123 B.US.00.RHPA_TF1.JN944917 B.US.00.THRO_TF1.JN944930
 B.US.00.WITO_TF1.JN944938 B.US.01.L805.FJ469738 B.US.01.REJO_TF1.JN944911 B.US.01.TRJO_TF1.JN944936 B.US.02.04013226_2_flH11.FJ496078
 B.US.02.CR0017Q.FJ469687 B.US.02.CR0058S.FJ469693 B.US.02.F706.FJ469728 B.US.02.F714.FJ469730 B.US.02.F719.FJ469734
 B.US.02.F797.FJ469737 B.US.02.HIV_US_BID_V5249_2002.JQ403102 B.US.02.HIV_US_BID_V5276_2002.JQ403105 B.US.02.L8124P.FJ469741
 B.US.02.L861P.FJ469748 B.US.02.MTF.FJ469751 B.US.02.PRLS08.FJ469757 B.US.02.PRLS09.FJ469758 B.US.02.PRLS16.FJ469760
 B.US.03.1BRHGA_E13_DP.KC312470 B.US.03.AT01480.FJ469686 B.US.03.CR0154X.FJ469701 B.US.03.DEMB03JP004.KC473846 B.US.03.F7157.FJ469731
 B.US.03.HDNDRPI032B2.GU562135 B.US.03.HIV_US_BID_V5279_2003.JQ403106 B.US.03.L8107.FJ469739 B.US.03.L8116.FJ469740
 B.US.03.L8152.FJ469742 B.US.03.PRLS01.FJ469753 B.US.03.PRLS12.FJ469759 B.US.03.PRLS24.FJ469764 B.US.03.PSL024B10.GU562272
 B.US.03.SH8233.FJ469770 B.US.04.014837G.FJ469684 B.US.04.CR0068P.FJ469695 B.US.04.CR0080N.FJ469697 B.US.04.CR0116Y.FJ469698
 B.US.04.CR0345Q.FJ469722 B.US.04.ES10_53.EF363127 B.US.04.ES11_2004_culture.KC935957 B.US.04.ES8_43.EF363126
 B.US.04.HIV_US_BID_V5258_2004.JQ403103 B.US.04.HIV_US_BID_V5261_2004.JQ403104 B.US.04.HIV_US_BID_V5282_2004.JQ403107
 B.US.04.SAMI_WGA1.EU547186 B.US.04.USPI71101EI7y04051pcWG2B9.JN024210 B.US.04.USPI83747EI6y04121pcWG2B5.JN024100 B.US.05.01144G.FJ469682
 B.US.05.012286G.FJ469683 B.US.05.04013396_0_flE6.FJ496081 B.US.05.05US_SAJ_NVS12.JF689852 B.US.05.05US_SAJ_NVS16.JF689854
 B.US.05.05US_SAJ_NVS3.JF689856 B.US.05.05US_SAJ_NVS5.JF689857 B.US.05.05US_SAJ_NVS8.JF689859 B.US.05.05US_SAJ_NVS9.JF689860
 B.US.05.502_0223_wg1.JF320059 B.US.05.502_1400_FL02.JF320043 B.US.05.502_2008_FL04.JF320484 B.US.05.502_2136_FL02.JF320185
 B.US.05.502_2495_wg02.JF320054 B.US.05.CR0175S.FJ469703 B.US.05.CR0307R.FJ469717 B.US.05.CR0312W.FJ469718 B.US.05.L8249.DQ886037
 B.US.05.L827.FJ469747 B.US.05.STCO_3_A2.KC312435 B.US.05.USPI38417EI33y05051pcWG2B2.JN024363 B.US.05.USPI88403EI14y05121pcWG2B7.JN024344
 B.US.06.06US_SAJ_C164_SC.JF689862 B.US.06.06US_SAJ_C165_TJ.JF689863 B.US.06.06US_SAJ_C166_SG.JF689864 B.US.06.06US_SAJ_C167_LH.JF689865
 B.US.06.06US_SAJ_C168_LS.JF689866 B.US.06.06US_SAJ_NVS22.JF689870 B.US.06.06US_SAJ_NVS23.JF689871 B.US.06.06US_SAJ_NVS27.JF689872
 B.US.06.06US_SAJ_NVS32.JF689874 B.US.06.06US_SAJ_NVS35.JF689875 B.US.06.06US_SAJ_NVS39.JF689876 B.US.06.502_0062_FL04.JF320613
 B.US.06.502_0176_FL06.JF320363 B.US.06.502_0227_FL05.JF320036 B.US.06.502_0309_wg13.JF320048 B.US.06.502_0322_RH04.JF320308
 B.US.06.502_0341_FL05.JF320003 B.US.06.502_0346_wg02.JF320097 B.US.06.502_0572_FL06.JF320038 B.US.06.502_0717_FL02.JF320526
 B.US.06.502_0762_RH05.JF320329 B.US.06.502_0839_wg01.JF320263 B.US.06.502_0897_RH05.JF320502 B.US.06.502_0923_wg07.JF320160
 B.US.06.502_0961_RH08.JF320011 B.US.06.502_1046_FL04.JF320564 B.US.06.502_1055_FL01.JF320169 B.US.06.502_1174_FL09.JF320053
 B.US.06.502_1211_FL01.JF320151 B.US.06.502_1512_FL01.JF320356 B.US.06.502_1619_FL06.JF320126 B.US.06.502_1919_RH01.JF320184
 B.US.06.502_2437_RH01.JF320592 B.US.06.502_2667_FL03.JF320145 B.US.06.701010068_E_J1.GU331147 B.US.06.BP00054_RH01.JN687749
 B.US.06.BP00055_RH01.JN687750 B.US.06.BP00057_RH02.JN687758 B.US.06.CH106_TF1.JN944897 B.US.06.CH40_TF1.JN944905
 B.US.06.CH58_TF1.JN944907 B.US.06.CH77_TF1.JN944909 B.US.06.CR0047U.FJ469691 B.US.06.CR0078.FJ469696 B.US.06.CR0131.FJ469700
 B.US.06.CR0215.FJ469708 B.US.06.CR0222X.FJ469709 B.US.06.CR0276Z.FJ469714 B.US.06.CR0361T.FJ469723 B.US.06.HIV_US_BID_V3047_2006.JQ403068
 B.US.06.HIV_US_BID_V4503_2006.JQ403095 B.US.06.HIV_US_BID_V4506_2006.JQ403097 B.US.06.HTM385B7.GU562266 B.US.07.07US_SAJ_C154.JF689877
 B.US.07.07US_SAJ_C156.JF689879 B.US.07.07US_SAJ_C161_H1.JF689883 B.US.07.07US_SAJ_C163_H3.JF689885 B.US.07.07US_SAJ_C166_MS.JF689886
 B.US.07.07US_SAJ_NVS42.JF689889 B.US.07.07US_SAJ_NVS48.JF689890 B.US.07.07US_SAJ_NVS54.JF689892 B.US.07.07US_SAJ_NVS55.JF689893
 B.US.07.306344_FL.JX863921 B.US.07.502_0938_RH04.JF320631 B.US.07.502_0965_RH01.JF320385 B.US.07.502_1115_wg1.JF320045
 B.US.07.502_1368_RH02.JF320173 B.US.07.502_1478_wg4.JF320150 B.US.07.502_1500_RH01.JF320387 B.US.07.502_1504_RH07.JF320394
 B.US.07.502_1518_RH03.JF320117 B.US.07.502_1709_04.JF320467 B.US.07.502_1897_wg6.JF320182 B.US.07.502_2000_RH03.JF320279
 B.US.07.502_2241_RH13.JF320539 B.US.07.502_2289_05.JF320197 B.US.07.502_2586_RH04.JF320131 B.US.07.BP00058_RH01.JN687759
 B.US.07.BP00063_RH01.JN687761 B.US.07.BP00064_RH01.JN687762 B.US.07.BP00067_RH01.JN687763 B.US.07.CR0027M.FJ469689
 B.US.07.CR0275.FJ469713 B.US.07.CR0339X.FJ469721 B.US.07.HIV_US_BID_V3010_2007.JQ403058 B.US.07.HIV_US_BID_V3020_2007.JQ403059
 B.US.07.HIV_US_BID_V3021_2007.JQ403060 B.US.07.HIV_US_BID_V3036_2007.JQ403064 B.US.07.HIV_US_BID_V3053_2007.JQ403071
 B.US.07.HIV_US_BID_V3115_2007.JQ403075 B.US.07.HIV_US_BID_V3120_2007.JQ403078 B.US.07.HIV_US_BID_V3512_2007.JQ403092
 B.US.07.HIV_US_BID_V3515_2007.JQ403093 B.US.07.HIV_US_BID_V4516_2007.JQ403096 B.US.07.MCST_B17.KC312583 B.US.07.WARO_A13.KC312386
 B.US.08.08US_SAJ_C202.JF689894 B.US.08.08US_SAJ_C203.JF689895 B.US.08.08US_SAJ_C204.JF689896 B.US.08.B.700010607.S.0dps.BF13.JX974238
 B.US.08.BP00061_RH01.JN687760 B.US.08.HIV_US_BID_V3024_2008.JQ403061 B.US.08.HIV_US_BID_V3032_2008.JQ403063
 B.US.08.HIV_US_BID_V3048_2008.JQ403069 B.US.08.HIV_US_BID_V3050_2008.JQ403070 B.US.08.HIV_US_BID_V3114_2007.JQ403074
 B.US.08.HIV_US_BID_V3128_2008.JQ403082 B.US.08.HIV_US_BID_V4120_2008.JQ403031 B.US.08.HIV_US_BID_V4124_2008.JQ403035
 B.US.08.HIV_US_BID_V4388_2008.JQ403083 B.US.08.HIV_US_BID_V4389_2008.JQ403084 B.US.08.HIV_US_BID_V4391_2008.JQ403086
 B.US.08.HIV_US_BID_V4392_2008.JQ403087 B.US.08.HIV_US_BID_V4393_2008.JQ403088 B.US.08.HIV_US_BID_V4394_2008.JQ403089
 B.US.08.HIV_US_BID_V4397_2008.JQ403091 B.US.08.HIV_US_BID_V4489_2008.JQ403094 B.US.09.C1P.GU733713 B.US.09.DEMB09US002.JX140657
 B.US.09.DEMB09US003.KC473824 B.US.09.ES38.KC935958 B.US.09.LTNP1.KC935959 B.US.10.10CB4_45E6.KF526141 B.US.10.C.HQ846913
 B.US.10.CP1.JN397365 B.US.10.DEMB10US001.KC473825 B.US.10.DEMB10US003.KC473826 B.US.10.DEMB10US004.KC473827
 B.US.10.DEMB10US007.KC473828 B.US.10.DEMB10US009.KC473829 B.US.10.DEMB10US011.KC473830 B.US.10.VC1.JN397364
 B.US.11.19CB1_induced.KF526228 B.US.11.20CB4_46F1.KF526265 B.US.11.22CC9_induced.KF526312 B.US.11.23CB6_induced.KF526323
 B.US.11.CP10_3A.KF384798 B.US.11.CP12_10.KF384799 B.US.11.CP13_2.KF384800 B.US.11.CP3_6.KF384801 B.US.11.CP4_2B.KF384802
 B.US.11.CP5_3A.KF384803 B.US.11.CP6_2E.KF384804 B.US.11.CP7_2B.KF384805 B.US.11.CP8_4.KF384806 B.US.11.CP9_1A.KF384807
 B.US.11.DEMB11US002.KC473831 B.US.11.DEMB11US004.KC473832 B.US.11.DEMB11US011.KC473834 B.US.11.DEMB11US015.KC473835
 B.US.11.ES22_27.KF384808 B.US.11.ES38.JN397362 B.US.11.ES39_42.KF384810 B.US.11.ES40_24.KF384811 B.US.11.VC3_14.KF384812
 B.US.11.VC5_3.KF384813 B.US.11.VC6_2.KF384814 B.US.83.SF2_LAV2_ARV2.K02007 B.US.84.MNCG_MN.M17449 B.US.84.SC.M17450 B.US.84.SF33.AY352275
 B.US.85.RJS4_15_ENVBB.M37573 B.US.86.5096_86.AY835749 B.US.86.5127_86.AY835774 B.US.86.AD87_ADA.AF004394 B.US.86.YU_2.M93258
 B.US.87.5113_87.AY835758 B.US.88.5160_88.AY835763 B.US.88.WR27.AF286365 B.US.89.P896_89_6.U39362 B.US.90.90US_873.AY713412
 B.US.90.US1.AY173952 B.US.90.US2.AY173953 B.US.90.WEAU160_GHOSH.U21135 B.US.91.5048_91.AY835761 B.US.91.DH12_3.AF069140
 B.US.91.R3A.AY608577 B.US.91.SUMA_TF1.JN944928 B.US.92.92US657_1_301657_1.U04908 B.US.94.5082_94.AY835773 B.US.94.94US_33931N.AY713410
 B.US.95.5073_95.AY835768 B.US.95.USPI90770EI72y95091pcWG2B7.JN024303 B.US.96.1027_05.AY331291 B.US.96.1057_01.AY331292
 B.US.96.5155_96.AY835753 B.US.96.USPI55751EI32y96071pcWG2B15.JN024428 B.US.97.1001_07.AY331282 B.US.97.1006_08.AY331284
 B.US.97.1012_08.AY331285 B.US.97.Ac_06.AY247251 B.US.97.ACTDM580208A15.GU562033 B.US.97.CQLDR03A1.GU562058 B.US.97.ZP6248_07_3A1.JN400469
 B.US.98.1058_08.AY331294 B.US.98.15384_1.DQ853463 B.US.98.98USHVTN1925c1.AY560107 B.US.98.98USHVTN3605c9.AY560108
 B.US.98.98USHVTN8229c6.AY560109 B.US.98.98USHVTN941c1.AY560110 B.US.98.ACT54869022A2.GU562001 B.US.98.HDNDRPI001B10.GU562080
 B.US.98.WC3_0498_4.EF175212 B.US.99.169_1999.JN599165 B.US.99.AD17_3C_TA4.GU331247 B.US.99.HIV_US_BID_V5239_1999.JQ403100
 B.US.99.PRB959_03.AY331296 B.US.x.1229I.FJ469685 B.US.x.AC_16_0_Days_Consen_fa.DQ127537 B.US.x.AC_59_41_Days_Seq1_fa.DQ127548
 B.US.x.AC160_T9_Day_1034_Dom.EU616649 B.US.x.CR0036W.FJ469690 B.US.x.CR0050Z.FJ469692 B.US.x.CR0059T.FJ469694
 B.US.x.CR0164U.FJ469702 B.US.x.CR0192W.FJ469704 B.US.x.CR0206U.FJ469705 B.US.x.CR0234.FJ469711 B.US.x.CR0248X.FJ469712
 B.US.x.CR0289Z.FJ469715 B.US.x.CR0317N.FJ469719 B.US.x.CR0382N.FJ469725 B.US.x.CR0413T.FJ469726 B.US.x.F701.FJ469727 B.US.x.F703.DQ886031
 B.US.x.F710.FJ469729 B.US.x.L8146.DQ886034 B.US.x.L8157.DQ886035 B.US.x.L8185.DQ886036 B.US.x.L8188.FJ469744 B.US.x.L896.FJ469750
 B.US.x.MACS2BR_9.AF491739 B.US.x.NC7.AF049495 B.US.x.NCQ.FJ469752 B.US.x.PRLS05.FJ469756 B.US.x.PRLS17.FJ469761 B.US.x.PRLS19.FJ469763
 B.US.x.PRLS28.FJ469766 B.US.x.sample_C_BID_D617.JX503075 B.US.x.SH8183.FJ469768 B.US.x.SH8229.FJ469769 B.US.x.SH8241.FJ469771
 B.UY.01.01UYTRA1092.AY781126 B.UY.01.01UYTRA1179.AY781127 B.UY.02.02UY_TSU1290.JN235958 B.UY.99.99UY_TRA0177.JN235965
 B.YE.02.02YE507.AY795904 B.YE.02.02YE508.AY795905 B.ZA.03.03ZAPS045MB2.DQ396398 B.ZA.85.R84.FJ647145 
Subtype C (n=336) 
C.AR.01.ARG4006.AY563170 C.BR.02.02BR2022.JN692434 C.BR.04.04BR021.AY727523 C.BR.04.04BR038.AY727524 C.BR.07.BP00040_RH01.JN687737
 C.BR.07.DEMC07BR003.JX140663 C.BR.92.BR025_d.U52953 C.BR.98.98BR004.AF286228 C.BW.00.00BW07621.AF443088 C.BW.00.00BW076820.AF443089
 C.BW.00.00BW087421.AF443090 C.BW.00.00BW147127.AF443091 C.BW.00.00BW16162.AF443092 C.BW.00.00BW1686.AF443093
 C.BW.00.00BW17593.AF443094 C.BW.00.00BW17732.AF443095 C.BW.00.00BW17956.AF443097 C.BW.00.00BW18113.AF443098 C.BW.00.00BW18595.AF443099
 C.BW.00.00BW18802.AF443100 C.BW.00.00BW192113.AF443101 C.BW.00.00BW20872.AF443104 C.BW.00.00BW2127214.AF443105
 C.BW.00.00BW22767.AF443107 C.BW.00.00BW38193.AF443108 C.BW.00.00BW38428.AF443109 C.BW.00.00BW38713.AF443110 C.BW.00.00BW3876_9.AF443111
 C.BW.00.00BW3886_8.AF443112 C.BW.00.00BW3970_2.AF443114 C.BW.00.00BW5031_1.AF443115 C.BW.96.96BW0504.AF110968
 C.BW.96.96BW06K18.AF290030 C.BW.96.96BW1104.AF110969 C.BW.96.96BW1210.AF110972 C.BW.96.96BW15B03.AF110973 C.BW.96.96BW16B01.AF110976
 C.BW.96.96BW17.AF110979 C.BW.96.96BWM032.AF443075 C.BW.96.96BWMO1_5.AF443074 C.BW.98.98BWMC122.AF443076 C.BW.98.98BWMC134.AF443077
 C.BW.98.98BWMC14A3.AF443078 C.BW.98.98BWMO36A5.AF443081 C.BW.99.99BW393212.AF443083 C.BW.99.99BW4745.AF443085
 C.BW.99.99BW47547.AF443086 C.BW.99.99BWMC168.AF443087 C.CN.06.06YNLC028sg.KC898980 C.CN.06.06YNLC32sg.KC899004 C.CN.07.07CNYN328.KF835515
 C.CN.07.07CNYN336.KF835522 C.CN.09.09YNLX090sg.KC898995 C.CN.09.09YNLX133sg.KC898996 C.CY.05.CY040.FJ388901 C.CY.05.CY069.FJ388913
 C.CY.06.CY166.FJ388948 C.CY.06.CY176.FJ388952 C.CY.07.CY187.JF683740 C.CY.07.CY205.JF683757 C.CY.08.CY219.JF683768
 C.CY.08.CY221.JF683770 C.CY.09.CY260.JF683803 C.DJ.91.DJ373A.L23065 C.DK.01.CTL_015.EF514713 C.ES.06.DEMC06ES003.KC473844
 C.ES.07.X2118_2.EU884500 C.ES.08.X2363_2.EU786681  
C.ET.02.02ET_288.AY713417 C.GE.03.03GEMZ033.DQ207941 C.IL.98.98IS002.AF286233 C.IL.99.99ET1.AY255823 C.IN.03.D24.EF469243
 C.IN.05.C.IN.05.NIRT723.1.KF766541                                       C.IN.09.T125_2139.KC156210 C.IN.93.93IN999.AF067154 C.IN.94.94IN476.AF286223
 C.IN.98.98IN012.AF286231 C.IN.98.98IN022.AF286232  C.IN.x.VB39.EF694033 C.IN.x.VB49.EF694035 C.KE.00.KER2010.AF457054
 C.KE.91.KNH1268.AY945738 C.MW.07.703010085_CH085.w4a.KC156211 C.MW.07.703010167_CH167.w8.KC156213 C.MW.07.703010228_CH228_TFa.KC156120
 C.MW.07.CH0010.w24.e11.KC148599C.MW.07.CH0047.w2.e11.KC148663 C.MW.08.4403bmLwk4_fl11.KF527172 C.MW.08.4419_301.KF527081
 C.MW.08.702010293_CH293.w8a.KC156216 C.MW.08.702010432_CH432.w4.KC156218 C.MW.08.702010440_CH440.w4.KC156219 C.MW.08.CH0275.w24.e1.KC149493
 C.MW.09.703010256_CH256.w96.KC156214 C.TZ.01.A125.AY253304 C.TZ.01.A207.AY253307 C.TZ.01.A246.AY253308 C.TZ.01.A301.AY253312
 C.TZ.01.A388.AY253317 C.TZ.01.A93.AY253303 C.TZ.01.BD16_10.AY253320 C.TZ.01.BD9_11.AY253322 C.TZ.02.CO178.AY734556
 C.TZ.02.CO328.AY734551 C.TZ.02.CO3305.AY734558 C.TZ.02.CO6130.AY734559 C.TZ.02.CO6721.AY734560 C.TZ.97.97TZ04.AF361874
 C.TZ.97.97TZ05.AF361875 C.TZ.98.98TZ013.AF286234 C.TZ.98.98TZ017.AF286235 C.US.11.17TB4_4G8.KF526226 C.US.98.98US_MSC3018.AY444800
 C.US.98.98US_MSC5016.AY444801 C.YE.02.02YE511.AY795906 C.ZA.00.1119MB.AY463229 C.ZA.00.1134MB.AY463217 C.ZA.00.1162MB.AY463224
 C.ZA.00.1165MB.AY463230 C.ZA.00.1168MB.AY463231 C.ZA.00.1170MB.AY463225 C.ZA.00.1171MB.AY463232 C.ZA.00.1189MB.AY838565
 C.ZA.00.1192M3M.AY463219 C.ZA.00.1195MB.AY463220 C.ZA.00.1210MB.AY463221 C.ZA.00.1217MB.AY463226 C.ZA.00.1225MB.AY463227
 C.ZA.01.2004MB.AY463235 C.ZA.01.2134MB.AY463237 C.ZA.02.02ZAPS005MB1.DQ351235 C.ZA.02.02ZAPS006MB1.DQ351220
 C.ZA.02.02ZAPS008MB1.DQ275647 C.ZA.02.02ZAPS015MB1.DQ369995 C.ZA.03.03ZAPS017MB1.DQ351224 C.ZA.03.03ZAPS020MB1.DQ275653
 C.ZA.03.03ZAPS021MB1.DQ369978 C.ZA.03.03ZAPS023MB1.DQ351225 C.ZA.03.03ZAPS024MB1.DQ396367 C.ZA.03.03ZAPS027MB1.DQ351223
 C.ZA.03.03ZAPS030MB1.DQ369996 C.ZA.03.03ZAPS032MB1.DQ445633 C.ZA.03.03ZAPS044MB1.DQ396384 C.ZA.03.03ZAPS046MB1.DQ369984
 C.ZA.03.03ZAPS049MB1.DQ369986 C.ZA.03.03ZAPS054MB2.DQ369988 C.ZA.03.03ZAPS055MB1.DQ396373 C.ZA.03.03ZAPS056MB1.DQ396374
 C.ZA.03.03ZAPS057MB2.DQ369989 C.ZA.03.03ZAPS059MB2.DQ445634 C.ZA.03.03ZAPS063MB1.DQ396388 C.ZA.03.03ZAPS066MB2.DQ396375
 C.ZA.03.03ZAPS067MB2.DQ396389 C.ZA.03.03ZAPS074MB2.DQ351228 C.ZA.03.03ZAPS081MB1.DQ351219 C.ZA.03.03ZAPS083MB1.DQ351229
 C.ZA.03.03ZAPS086MB1.DQ275654 C.ZA.03.03ZAPS097MB1.DQ351230 C.ZA.03.03ZAPS099MB1.DQ275655 C.ZA.03.03ZAPS103MB2.DQ275656
 C.ZA.03.03ZAPS105MB2.DQ445632 C.ZA.03.03ZAPS108MB1.DQ396378 C.ZA.03.03ZAPS112MB2.DQ396386 C.ZA.03.03ZAPS113MB2.DQ396365
 C.ZA.03.03ZAPS118MB1.DQ396368 C.ZA.03.03ZAPS124MB1.DQ369976 C.ZA.03.03ZAPS130MB1.DQ275658 C.ZA.03.03ZAPS136MB1.DQ351231
 C.ZA.03.03ZAPS140MB1.DQ369981 C.ZA.03.03ZAPS143MB1.DQ396391 C.ZA.03.03ZAPS151MB1.DQ396392 C.ZA.03.03ZAPS152MB1.DQ396399
 C.ZA.03.03ZAPS155MB1.DQ396371 C.ZA.03.03ZASK005B2.DQ011175 C.ZA.03.03ZASK010B2.DQ164104 C.ZA.03.03ZASK011B2.AY901965
 C.ZA.03.03ZASK016MB2.DQ351233 C.ZA.03.03ZASK019B2.AY878063 C.ZA.03.03ZASK020B2.AY878064 C.ZA.03.03ZASK034B1.AY878065 C.ZA.03.03ZASK039B2.AY878068
 C.ZA.03.03ZASK061B1.AY901968 C.ZA.03.03ZASK062B1.DQ164113 C.ZA.03.03ZASK066B1.AY901969 C.ZA.03.03ZASK067B1.DQ275642
 C.ZA.03.03ZASK073B1.AY901970 C.ZA.03.03ZASK076B1.AY901975 C.ZA.03.03ZASK092B1.AY878057 C.ZA.03.03ZASK097B1.AY878060 C.ZA.03.03ZASK098B1.AY878061
 C.ZA.03.03ZASK103B1.DQ164106 C.ZA.03.03ZASK104B1.DQ396395 C.ZA.03.03ZASK107B1.DQ056410 C.ZA.03.03ZASK110B1.DQ056411
 C.ZA.03.03ZASK117B1.DQ056408 C.ZA.03.03ZASK120B1.DQ011176 C.ZA.03.03ZASK215M6W.DQ275661 C.ZA.03.03ZASK232B1.DQ093589
 C.ZA.03.03ZASK233B1.DQ351234 C.ZA.03.04ZASK082B1.AY901972 C.ZA.03.SK029B2.AY772691 C.ZA.03.SK040B1.AY703908 C.ZA.03.SK041B1.AY772693
 C.ZA.03.SK043B1.AY772700 C.ZA.03.SK065B1.AY772694 C.ZA.03.SK091B1.AY772701 C.ZA.03.SK112B1.AY772695 C.ZA.03.SK116B1.AY772696
 C.ZA.04.04ZAPS157MB1.DQ351232 C.ZA.04.04ZAPS160B1.DQ164107 C.ZA.04.04ZAPS161B1.DQ164115 C.ZA.04.04ZAPS168B1.DQ164121
 C.ZA.04.04ZAPS172MB1.DQ275659 C.ZA.04.04ZAPS177MB1.DQ396394 C.ZA.04.04ZAPS188B1.DQ164122 C.ZA.04.04ZAPS189B1.DQ164117
 C.ZA.04.04ZAPS190B1.DQ093602 C.ZA.04.04ZAPS195B1.DQ164118 C.ZA.04.04ZAPS197MB1.DQ369997 C.ZA.04.04ZAPS198MB1.DQ445637
 C.ZA.04.04ZAPS199B1.DQ164110 C.ZA.04.04ZAPS202B1.DQ093598 C.ZA.04.04ZAPS205B1.DQ093599 C.ZA.04.04ZAPS206B1.DQ164126
 C.ZA.04.04ZAPS211B1.DQ164112 C.ZA.04.04ZAPS214B1.DQ093588 C.ZA.04.04ZAPS216B1.DQ093600 C.ZA.04.04ZAPS217B1.DQ164119
 C.ZA.04.04ZASK031B2.AY901974 C.ZA.04.04ZASK083B2.DQ093585 C.ZA.04.04ZASK127B1.DQ011172 C.ZA.04.04ZASK128B1.DQ093586
 C.ZA.04.04ZASK131B1.DQ056412 C.ZA.04.04ZASK132B1.DQ093594 C.ZA.04.04ZASK135B1.DQ011166 C.ZA.04.04ZASK136B1.DQ011177
 C.ZA.04.04ZASK139B1.AY878072 C.ZA.04.04ZASK142B1.DQ011167 C.ZA.04.04ZASK145B1.AY901976 C.ZA.04.04ZASK146.AY772699 C.ZA.04.04ZASK147B1.DQ164114
 C.ZA.04.04ZASK150B1.DQ011178 C.ZA.04.04ZASK154B1.AY878071 C.ZA.04.04ZASK159B1.DQ011179 C.ZA.04.04ZASK161B1.DQ011170
 C.ZA.04.04ZASK167B1.DQ164127 C.ZA.04.04ZASK170B1.DQ093595 C.ZA.04.04ZASK173B1.DQ093604 C.ZA.04.04ZASK175B1.DQ164129
 C.ZA.04.04ZASK176B1.DQ056416 C.ZA.04.04ZASK180B1.AY878059 C.ZA.04.04ZASK181B1.AY878062 C.ZA.04.04ZASK182B1.AY878054 C.ZA.04.04ZASK184B1.DQ056418
 C.ZA.04.04ZASK190B1.DQ056409 C.ZA.04.04ZASK192B1.DQ396382 C.ZA.04.04ZASK193B1.DQ396396 C.ZA.04.04ZASK196B1.DQ056413
 C.ZA.04.04ZASK201B1.DQ396397 C.ZA.04.04ZASK202B1.DQ011180 C.ZA.04.04ZASK206B1.DQ056415 C.ZA.04.04ZASK217B1.DQ056417
 C.ZA.04.04ZASK234B1.DQ093605 C.ZA.04.CAP30_5w_F4.GQ999973 C.ZA.04.CAP61_8w_F3.GQ999975 C.ZA.04.SK134B1.AY703909
 C.ZA.04.SK143B1.AY703910 C.ZA.04.SK144B1.AY703911 C.ZA.05.05ZASK244B1.DQ369992 C.ZA.05.05ZASK245B1.DQ369982
 C.ZA.05.05ZASK247B1.DQ369994 C.ZA.05.CAP206_8w_F1.GQ999982 C.ZA.05.CAP210_5w.GQ999983 C.ZA.05.CAP228_8w_F2.GQ999984
 C.ZA.05.CAP229_7w.GQ999985 C.ZA.05.CAP244_8w_F1.GQ999986 C.ZA.05.CAP248_9w.GQ999987 C.ZA.05.CAP256_6w.GQ999989 C.ZA.05.CAP257_7w_F1.GQ999990
 C.ZA.05.CAP63_5w_F4.GQ999976 C.ZA.05.CAP65_6w.GQ999977 C.ZA.05.CAP8_3w_F2.GQ999972 C.ZA.05.CAP85_5w_F1.GQ999979
 C.ZA.05.CAP88_5w_F2.GQ999980 C.ZA.07.704010042_CH042_TF.KC156123 C.ZA.07.705010067_CH067_TF.KC156125 C.ZA.07.705010162_CH162.mo6.KC156115
 C.ZA.07.705010198_CH198_TF.KC156130 C.ZA.07.706010164_CH164_TF.KC156127 C.ZA.07.BP00005_RH03.JN687704 C.ZA.07.BP00008_RH01.JN687706
 C.ZA.07.BP00009_SUP_RH01.JN687717 C.ZA.07.BP00035_RH01.JN687736 C.ZA.07.DEMC07ZA011.JX140664 C.ZA.08.705010185_CH185.mo6.KC156116
 C.ZA.08.BP00012_RH01.JN687724 C.ZA.08.BP00014_RH01.JN687725 C.ZA.08.BP00018_RH01.JN687728 C.ZA.08.BP00023_RH02.JN687730
 C.ZA.08.BP00025_RH02.JN687731 C.ZA.08.DEMC08ZA011.JX140666 C.ZA.09.DEMC09ZA008.JX140667 C.ZA.09.DEMC09ZA009.JX140668
 C.ZA.10.DEMC10ZA001.JX140669 C.ZA.90.pZAC_R3714.JN188292 C.ZA.97.97ZA003.AY118165 C.ZA.97.97ZA009.AY118166 C.ZA.97.97ZA012.AF286227
 C.ZA.98.98ZA502.AY158534 C.ZA.98.98ZA528.AY158535 C.ZA.98.CTSC2.AY043176 C.ZA.98.DU151.AY043173 C.ZA.98.TV012.AY162225
 C.ZA.99.99ZALT21.EU293446 C.ZA.99.99ZALT39.EU293447 C.ZA.99.99ZALT4.EU293444 C.ZA.99.99ZALT42.EU293448 C.ZA.99.99ZALT45.EU293449
 C.ZA.99.99ZALT46.EU293450 C.ZA.99.99ZALT5.EU293445 C.ZA.99.99ZATM10.AY228556 C.ZA.99.DU179.AY043174 C.ZA.99.ZASW7.AF411966
 C.ZM.02.02ZM114.AB254146 C.ZM.02.02ZM115.AB254148 C.ZM.02.02ZMBC.AB254149 C.ZM.02.02ZMDB.AB254153 C.ZM.02.02ZMJM.AB254156
 C.ZM.03.ZM246F_flA10.FJ496186 C.ZM.03.ZM247F_flA1.FJ496195 C.ZM.03.ZM249M_flC1.FJ496209 C.ZM.11.DEMC11ZM006.KF716467
 C.ZM.96.96ZM651.AF286224 C.ZM.96.96ZM751.AF286225 C.ZM.x.HIV1084i.AY805330   
Subtype D (n=52) 
D.CD.84.84ZR085.U88822 D.CD.85.Z2Z6_Z2_CDC_Z34.M22639 D.CM.01.01CM_0009BBY.AY371155 D.CM.01.01CM_0175BA.AY371156
 D.CM.01.01CM_4412HAL.AY371157 D.CM.10.DEMD10CM009.JX140670 D.CY.06.CY163.FJ388945 D.KE.01.NKU3006.AF457090
 D.KE.11.DEMD11KE003.KF716476 D.KE.97.ML415_2.AY322189 D.KR.04.04KBH8.DQ054367 D.SN.90.SE365A2.L22945 D.TD.99.MN011.AJ488926
 D.TD.99.MN012.AJ488927 D.TZ.01.A280.AY253311 D.UG.05.p190049.JX236668 D.UG.07.p191647.JX236670 D.UG.07.p191882.JX236673
 D.UG.07.pSC191727.JX236679 D.UG.08.p191859.JX236672 D.UG.10.DEMD10UG004.KF716479 D.UG.11.DEMD11UG003.KF716480
 D.UG.91.UG270.AB485650 D.UG.93.93UG_065.AY713418 D.UG.94.94UG114.U88824 D.UG.98.98UG57128.AF484502 D.UG.98.98UG57130.AF484504
 D.UG.98.98UG57131.AF484505 D.UG.98.98UG57132.AF484506 D.UG.98.98UG57140.AF484511 D.UG.98.98UG57143.AF484514 D.UG.98.98UG57146.AF484513
 D.UG.98.99UGJ32228.AF484516 D.UG.99.99UGA03349.AF484518 D.UG.99.99UGA08483.AY304496 D.UG.99.99UGB25647.AF484481 D.UG.99.99UGB32394.AF484483
 D.UG.99.99UGD23550.AF484485 D.UG.99.99UGD26830.AF484486 D.UG.99.99UGE08364.AF484487 D.UG.99.99UGE13613.AF484515 D.UG.99.99UGF03726.AF484519
 D.UG.99.99UGF05734.AF484490 D.UG.99.99UGG10555.AF484494 D.UG.99.99UGG35093.AF484495 D.UG.99.99UGK09259.AF484498 D.UG.99.99UGK09958.AF484499
 D.US.07.HIV_US_BID_V3121_2007.JQ403079 D.YE.01.01YE386.AY795903 D.YE.02.02YE516.AY795907 D.ZA.85.R286.AY773340 D.ZA.90.R1.EF633445  
Subtype F (n=27)  
F1.AO.06.AO_06_ANG125.FJ900269 F1.AO.06.AO_06_ANG32.FJ900266 F1.AO.06.AO_06_ANG40.FJ900267 F1.AO.06.AO_06_ANG58.FJ900268 
F1.AR.02.ARE933.DQ189088 F1.BE.93.VI850.AF077336 F1.BR.02.02BR082.FJ771006 F1.BR.02.02BR170.FJ771007 F1.BR.06.06BR564.FJ771008 
F1.BR.06.06BR579.FJ771009 F1.BR.07.07BR844.FJ771010 F1.BR.89.BZ163.AY173958 F1.BR.93.93BR020_1.AF005494 F1.CY.08.CY222.JF683771 
F1.DE.x.MVP_30846.EU446022 F1.ES.02.ES_X845_4.FJ670516 F1.ES.x.X1093_2.DQ979025 F1.ES.x.X1670.DQ979024 F1.FI.93.FIN9363.AF075703 
F1.FR.96.96FR_MP411.AJ249238 F1.RO.96.BCI_R07.AB485658 F2.CM.02.02CM_0016BBY.AY371158 F2.CM.10.DEMF210CM001.JX140672 
                 
                 
F2.CM.10.DEMF210CM007.JX140673 F2.CM.95.95CM_MP255.AJ249236 F2.CM.95.95CM_MP257.AJ249237 F2.CM.97.CM53657.AF377956  
Subtype G (n=30) 
                    G.CM.01.01CM_4049HAN.AY371121 G.CM.04.178_15.FJ389363 G.CM.04.944_5.FJ389366 G.CM.10.DEMG10CM008.JX140676
 G.CN.06.sh52.HM067749 G.CN.08.GX_2084_08.JN106043 G.CU.99.Cu74.AY586547 G.CU.99.Cu85.AY586548 G.ES.00.X558.AF423760
 G.ES.05.P962.EU786670 G.ES.08.P1981_2.FJ670530 G.ES.09.X2634_2.GU362882 G.GH.03.03GH175G.AB287004 G.KE.09.DEMG09KE001.KF716477
 G.KE.93.HH8793_12_1.AF061641 G.NG.01.01NGPL0669.DQ168576 G.NG.01.01NGPL0674.DQ168575 G.NG.01.01NGPL0760.DQ168579
 G.NG.01.PL0567.DQ168573 G.NG.08.08NG_SC13.JN248582 G.NG.09.09NG_SC21.JN248584 G.NG.09.09NG_SC26.JN248586 G.NG.09.09NG_SC31.JN248591
 G.NG.09.09NG_SC62.JN248593 G.NG.92.92NG083_JV10832.U88826 G.PT.x.PT2695.AY612637 G.PT.x.PT3037.FR846408 G.PT.x.PT3306.FR846409
 G.PT.x.PT988.FR846410 G.SE.93.SE6165_G6165.AF061642           
Subtype H (n=4) 
                   H.BE.93.VI991.AF190127       H.BE.93.VI997.AF190128   H.CF.90.056.AF005496    H.GB.00.00GBAC4001.FJ711703  
Subtype J (n=2) 
                   J.CD.97.J_97DC_KTB147.EF614151 J.SE.94.SE9173_7022.AF082395          
Subtype K (n=2) 
                  K.CD.97.97ZR_EQTB11.AJ249235      K.CM.96.96CM_MP535.AJ24923 
  
 







Continent B C Total 
Asia 80 9 89 
(11.5%) 
Africa 2 254 256 
(33.1%) 
Europe 94 8 102 
(13.2%) 
South America 78 7 85 
(11.0%) 
North America 228 2 230 
(29.8%) 








Appendix Table 2b: Accession numbers of the Full-length Tat in subtypes B and 
C obtained from the Los Alamos National Laboratory (LANL) HIV sequence 
(Data set 2) 

























































































































































































































































































B.US.02.PRLS08.FJ46975702   
B.US.02.PRLS09.FJ46975802   
B.US.02.PRLS16.FJ46976002   
B.US.03.CR0154X.FJ46970103   
B.US.03.F7157.FJ46973103   
B.US.03.HIV_US_BID_V5279_2003.JQ40310603   
B.US.03.L8107.FJ46973903   
B.US.03.L8116.FJ46974003   
B.US.03.L8152.FJ46974203   
B.US.03.L8180.FJ46974303   
B.US.03.PRLS01.FJ46975303   
B.US.03.PRLS12.FJ46975903   
B.US.03.PRLS24.FJ46976403   
B.US.03.PSL024B10.GU56227203   
B.US.03.SH8233.FJ46977003   
B.US.04.014837G.FJ46968404   
B.US.04.CR0068P.FJ46969504   
B.US.04.CR0080N.FJ46969704   
B.US.04.CR0116Y.FJ46969804   
B.US.04.CR0345Q.FJ46972204   
B.US.04.ES10_53.EF36312704   
B.US.04.ES8_43.EF36312604   
B.US.04.F7165.FJ46973204   
B.US.04.HDNDRPI034A4.GU56215504   
B.US.04.HIV_US_BID_V5258_2004.JQ40310304   
B.US.04.HIV_US_BID_V5261_2004.JQ40310404   
B.US.04.HIV_US_BID_V5282_2004.JQ40310704   
B.US.04.USPI71101EI7y04051pcWG2B9.JN02421004   
B.US.04.USPI83747EI6y04121pcWG2B5.JN02410004   
B.US.05.01144G.FJ46968205   
B.US.05.012286G.FJ46968305   
B.US.05.04013396_0_flE6.FJ49608105   
B.US.05.05US_SAJ_NVS12.JF68985205   
B.US.05.05US_SAJ_NVS16.JF68985405   
B.US.05.05US_SAJ_NVS3.JF68985605   
B.US.05.05US_SAJ_NVS5.JF68985705   
B.US.05.05US_SAJ_NVS8.JF68985905   
B.US.05.05US_SAJ_NVS9.JF68986005   
B.US.05.502_0223_wg1.JF32005905   
B.US.05.502_1400_FL02.JF32004305   
B.US.05.502_1926_FL01.JF32036105   
B.US.05.502_2008_FL04.JF32048405   
B.US.05.502_2136_FL02.JF32018505   
B.US.05.502_2495_wg02.JF32005405   
B.US.05.CR0175S.FJ46970305   
B.US.05.CR0307R.FJ46971705   
B.US.05.CR0312W.FJ46971805   
B.US.05.L8249.DQ88603705   
B.US.05.L827.FJ46974705   
B.US.05.USPI38417EI33y05051pcWG2B2.JN02436305   
B.US.05.USPI88403EI14y05121pcWG2B7.JN02434405   
B.US.06.06US_SAJ_C164_SC.JF68986206   
B.US.06.06US_SAJ_C165_TJ.JF68986306   
B.US.06.06US_SAJ_C168_LS.JF68986606   
B.US.06.06US_SAJ_C169_JS.JF68986706   
B.US.06.06US_SAJ_NVS22.JF68987006   
B.US.06.06US_SAJ_NVS23.JF68987106   
B.US.06.06US_SAJ_NVS27.JF68987206   
B.US.06.06US_SAJ_NVS32.JF68987406   
B.US.06.06US_SAJ_NVS35.JF68987506   
B.US.06.06US_SAJ_NVS39.JF68987606   
B.US.06.502_0053_wg06.JF32061506   
B.US.06.502_0062_FL04.JF32061306   
B.US.06.502_0176_FL06.JF32036306   
B.US.06.502_0227_FL05.JF32003606   
B.US.06.502_0309_wg13.JF32004806   
B.US.06.502_0322_RH04.JF32030806   
B.US.06.502_0341_FL05.JF32000306   
B.US.06.502_0346_wg02.JF32009706   
B.US.06.502_0572_FL06.JF32003806   
B.US.06.502_0717_FL02.JF32052606   
B.US.06.502_0762_RH05.JF32032906   
B.US.06.502_0839_wg01.JF32026306   
B.US.06.502_0897_RH05.JF32050206   
B.US.06.502_0923_wg07.JF32016006   
B.US.06.502_1055_FL01.JF32016906   
B.US.06.502_1174_FL09.JF32005306   
B.US.06.502_1512_FL01.JF32035606   
B.US.06.502_1619_FL06.JF32012606   
B.US.06.502_2437_RH01.JF32059206   
B.US.06.502_2667_FL03.JF32014506   
B.US.06.BP00054_RH01.JN68774906   
B.US.06.CH40_TF1.JN94490506   
B.US.06.CH58_TF1.JN94490706   
B.US.06.CH77_TF1.JN94490906   
B.US.06.CR0047U.FJ46969106   
B.US.06.CR0078.FJ46969606   
B.US.06.CR0131.FJ46970006   
B.US.06.CR0215.FJ46970806   
B.US.06.CR0222X.FJ46970906   
B.US.06.CR0228Q.FJ46971006   
B.US.06.CR0276Z.FJ46971406   
B.US.06.CR0361T.FJ46972306   
B.US.06.HIV_US_BID_V3047_2006.JQ40306806   
B.US.06.HIV_US_BID_V4506_2006.JQ40309706   
B.US.06.HTM385B7.GU56226606   
B.US.07.07US_SAJ_C154.JF68987707   
B.US.07.07US_SAJ_C161_H1.JF68988307   
B.US.07.07US_SAJ_C163_H3.JF68988507   
B.US.07.07US_SAJ_C166_MS.JF68988607   
B.US.07.07US_SAJ_NVS48.JF68989007   
B.US.07.07US_SAJ_NVS54.JF68989207   
B.US.07.07US_SAJ_NVS55.JF68989307   
B.US.07.502_0287_RH1.JF32037507   
B.US.07.502_0364_wg2.JF32056307   
B.US.07.502_0388_RH06.JF32031507   
B.US.07.502_0823_05.JF32053007   
B.US.07.502_0938_RH04.JF32063107   
B.US.07.502_0965_RH01.JF32038507   
B.US.07.502_1115_wg1.JF32004507   
B.US.07.502_1368_RH02.JF32017307   
B.US.07.502_1478_wg4.JF32015007   
B.US.07.502_1500_RH01.JF32038707   
B.US.07.502_1897_wg6.JF32018207   
B.US.07.502_2000_RH03.JF32027907   
B.US.07.502_2241_RH13.JF32053907   
B.US.07.502_2289_05.JF32019707   
B.US.07.502_2305_01.JF32057707   
B.US.07.502_2586_RH04.JF32013107   
B.US.07.BP00058_RH01.JN68775907   
B.US.07.BP00064_RH01.JN68776207   
B.US.07.BP00067_RH01.JN68776307   
B.US.07.CR0027M.FJ46968907   
B.US.07.CR0214.FJ46970707   
B.US.07.CR0275.FJ46971307   
B.US.07.CR0295S.FJ46971607   
B.US.07.CR0339X.FJ46972107   
B.US.07.HIV_US_BID_V3010_2007.JQ40305807   
B.US.07.HIV_US_BID_V3020_2007.JQ40305907   
B.US.07.HIV_US_BID_V3021_2007.JQ40306007   
B.US.07.HIV_US_BID_V3036_2007.JQ40306407   
B.US.07.HIV_US_BID_V3053_2007.JQ40307107   
B.US.07.HIV_US_BID_V3115_2007.JQ40307507   
B.US.07.HIV_US_BID_V3120_2007.JQ40307807   
B.US.07.HIV_US_BID_V3515_2007.JQ40309307   
B.US.07.HIV_US_BID_V4516_2007.JQ40309607   
B.US.08.08US_SAJ_C203.JF68989508   
B.US.08.08US_SAJ_C204.JF68989608   
B.US.08.BP00061_RH01.JN68776008   
B.US.08.HIV_US_BID_V3024_2008.JQ40306108   
B.US.08.HIV_US_BID_V3027_2008.JQ40306208   
B.US.08.HIV_US_BID_V3046_2008.JQ40306708   
B.US.08.HIV_US_BID_V3048_2008.JQ40306908   
B.US.08.HIV_US_BID_V3050_2008.JQ40307008   
B.US.08.HIV_US_BID_V3114_2007.JQ40307408   
B.US.08.HIV_US_BID_V3122_2008.JQ40308008   
B.US.08.HIV_US_BID_V3128_2008.JQ40308208   
B.US.08.HIV_US_BID_V4124_2008.JQ40303508   
B.US.08.HIV_US_BID_V4388_2008.JQ40308308   
B.US.08.HIV_US_BID_V4389_2008.JQ40308408   
B.US.08.HIV_US_BID_V4390_2008.JQ40308508   
B.US.08.HIV_US_BID_V4391_2008.JQ40308608   
B.US.08.HIV_US_BID_V4392_2008.JQ40308708   
B.US.08.HIV_US_BID_V4393_2008.JQ40308808   
B.US.08.HIV_US_BID_V4394_2008.JQ40308908   
B.US.08.HIV_US_BID_V4489_2008.JQ40309408   
B.US.09.DEMB09US002.JX14065709   
B.US.10.CP1.JN39736510   
B.US.10.VC1.JN39736410   
B.US.11.ES38.JN39736211   
B.US.83.RF_HAT3.M1745183   
B.US.84.MNCG_MN.M1744984   
B.US.84.SC.M1745084   
B.US.84.SF33.AY35227584   
B.US.85.RJS4_15_ENVBB.M3757385   
B.US.86.5127_86.AY83577486   
B.US.86.AD87_ADA.AF00439486   
B.US.86.YU_2.M9325886   
B.US.87.5113_87.AY83575887   
B.US.88.5160_88.AY83576388   
B.US.88.WR27.AF28636588   
B.US.89.P896_89_6.U3936289   
B.US.90.US1.AY17395290   
B.US.90.US2.AY17395390   
B.US.90.US4.AY17395590   
B.US.90.WEAU160_GHOSH.U2113590   
B.US.91.5048_91.AY83576191   
B.US.91.DH12_3.AF06914091   
B.US.91.R3A.AY60857791   
B.US.91.SUMA_TF1.JN94492891   
B.US.92.92US657_1_301657_1.U0490892   
B.US.94.5082_94.AY83577394   
B.US.94.94US_33931N.AY71341094   
B.US.95.5073_95.AY83576895   
B.US.96.1027_05.AY33129196   
B.US.96.1057_01.AY33129296   
B.US.96.5155_96.AY83575396   
B.US.96.USPI55751EI32y96071pcWG2B15.JN02442896   
B.US.97.1006_08.AY33128497   
B.US.97.1012_08.AY33128597   
B.US.97.1018_06.AY33128997   
B.US.97.Ac_06.AY24725197   
B.US.97.ACTDM580208A15.GU56203397   
B.US.97.CQLDR03A1.GU56205897   
B.US.97.HTM319C1.GU56223697   
B.US.97.ZP6248_07_3A1.JN40046997   
B.US.98.1058_08.AY33129498   
B.US.98.98USHVTN3605c9.AY56010898   
B.US.98.98USHVTN941c1.AY56011098   
B.US.98.HDNDRPI001B10.GU56208098   
B.US.98.WC3_0498_4.EF17521298   
B.US.99.169_1999.JN59916599   
B.US.99.HIV_US_BID_V5239_1999.JQ40310099   
B.US.99.PRB959_03.AY33129699   
B.UY.01.01UYTRA1092.AY78112601   
B.UY.01.01UYTRA1179.AY78112701   
B.UY.02.02UY_TSU1290.JN23595802   
B.VE.10.DEMB10VE001.JX14065910   
B.YE.02.02YE508.AY79590502   
B.ZA.03.03ZAPS045MB2.DQ39639803   
Ref.B.NL.00.671_00T36.AY42338700   
Ref.B.TH.90.BK132.AY17395190   
Ref.B.US.98.1058_11.AY33129598   
 








Continent B C Total 
Asia 29 8 37 
(19.7%) 
Africa 2 32 34 
(18.1%) 
Europe 36 6 42 
(22.3%) 
South America 24 5 29 
(15.4%) 
North America 37 2 39 
(20.7%) 








Appendix Table 3b: Accession numbers of the Full-length Tat in subtypes B 
and C obtained from the Los Alamos National Laboratory (LANL) HIV 
sequence (Data set 3) 






















































B.EC.89.EC003.AY173959.1989   
B.ES.05.X1890.EU786672.2005   
B.ES.06.X2102.EU786677.2006   
B.ES.07.X2210_3.EU786679.2007   
B.ES.08.ES_X2515_3.GQ372988.2008   
B.ES.09.X2689_2.GU362885.2009   
B.FR.08.DEMB08FR002.JX140654.2008   
B.GA.88.OYI_397.M26727.1988   
B.GB.03.MM33d12p.HM586187.2003   
B.GB.04.MM39d11p.HM586193.2004   
B.GB.05.MM43d368_GN1.HM586209.2005   
B.GB.83.CAM1.D10112.1983   
B.GB.86.GB8_46R.AJ271445.1986   
B.GE.03.03GEMZ010.DQ207942.2003   
B.HK.06.HK002.FJ460499.2006   
B.HT.05.05HT_129473.EU839603.2005   
B.JM.05.05JM_KJ108.EU839605.2005   
B.JM.09.09JM_PF09XN.HM030559.2009   
B.JP.00.DR2508.AB289588.2000   
B.JP.01.DR388.AB289590.2001   
B.JP.04.DR5913.AB480696.2004   
B.JP.05.426.AB428556.2005   
B.KR.02.02OSG1.JQ429433.2002   
B.KR.03.03HJY8.JQ316131.2003   
B.KR.04.04KJS8.JQ316130.2004   
B.KR.05.05CSR3.DQ837381.2005   
B.KR.07.07KYY4.JQ341411.2007   
B.KR.97.WK.AF224507.1997   
B.NL.99.671_99T12.AY423381.1999   
B.PE.06.502_0491_wg5.JF320183.2006   
B.PE.07.502_0525_wg5.JF320191.2007   
B.PL.08.BP00074_RH02.JN687774.2008   
B.PY.02.02PY_PSP0019.JN251896.2002   
B.PY.03.03PY_PSP0115.JN251906.2003   
B.RU.04.04RU128005.AY682547.2004   
B.RU.09.09RU4457.JX500709.2009   
B.RU.11.11RU21n.JX500708.2011   
B.TH.04.04TH317223.JN248321.2004   
B.TH.05.05TH356764.JN248344.2005   
B.TH.06.AA010a_WG3.JX446800.2006   
B.TH.07.AA040a_WG11.JX447156.2006   
B.TH.08.AA115c03R.JX448103.2008   
B.TH.96.M145.DQ354118.1996   
B.TT.00.00TT_CRC50018.EU839607.2002   
B.TW.94.TWCYS_LM49.AF086817.1994   
B.UA.01.01UAKV167.DQ823362.2001   
B.US.00.ES1_20.EF363123.2000   
B.US.01.L805.FJ469738.2001   
B.US.02.F706.FJ469728.2002   
B.US.03.L8107.FJ469739.2003   
B.US.04.CR0345Q.FJ469722.2004   
B.US.05.012286G.FJ469683.2005   
B.US.06.06US_SAJ_NVS23.JF689871.2006   
B.US.07.07US_SAJ_C154.JF689877.2007   
B.US.08.08US_SAJ_C203.JF689895.2008   
B.US.09.DEMB09US002.JX140657.2009   
B.US.10.CP1.JN397365.2010   
B.US.11.ES38.JN397362.2011   
B.US.83.RF_HAT3.M17451.1983   
B.US.84.MNCG_MN.M17449.1984   
B.US.85.RJS4_15_ENVBB.M37573.1985   
B.US.86.5127_86.AY835774.1986   
B.US.87.5113_87.AY835758.1987   
B.US.88.5160_88.AY835763.1988   
B.US.89.P896_89_6.U39362.1989   
B.US.90.US1.AY173952.1990   
B.US.91.DH12_3.AF069140.1991   
B.US.92.92US657_1_301657_1.U04908.1992   
B.US.94.5082_94.AY835773.1994   
B.US.95.5073_95.AY835768.1995   
B.US.96.5155_96.AY835753.1996   
B.US.97.1006_08.AY331284.1997   
B.US.98.WC3_0498_4.EF175212.1998   
B.US.99.169_1999.JN599165.1999   
B.UY.01.01UYTRA1179.AY781127.2001   
B.UY.02.02UY_TSU1290.JN235958.2002   
B.VE.10.DEMB10VE001.JX140659.2010   
B.YE.02.02YE508.AY795905.2002   
B.ZA.03.03ZAPS045MB2.DQ396398.2003   
Ref.B.FR.83.HXB2_LAI_IIIB_BRU.K03455  
Ref.B.NL.00.671_00T36.AY423387.2000  
Ref.B.TH.90.BK132.AY173951.1990  
Ref.B.US.98.1058_11.AY331295.1998  
 
